vicki
yang
dawn
meola
sarah
crain
kristen
thane
airiel
davi
andrew
hoffman
tuft
univers
cum
school
veterinari
medicin
north
grafton
massachusett
usa
myxomat
mitral
valv
diseas
mmvd
common
acquir
cardiac
diseas
dog
common
caus
congest
heart
failur
dog
chronic
valvular
diseas
lead
valvular
insuffici
cardiac
enlarg
sometim
contractil
dysfunct
later
stage
diseas
diseas
progress
amount
valvular
regurgit
increas
eventu
lead
volum
overload
pulmonari
venou
congest
final
congest
heart
failur
pulmonari
edema
common
histolog
find
seen
myxomat
valv
includ
disarray
collagen
elastin
fiber
well
disrupt
microstructur
within
valv
disarray
disorgan
partli
result
phenotyp
transdifferenti
valvular
interstiti
cell
vic
quiescent
fibroblast
cell
cell
follow
classic
paradigm
fibrogenesi
transform
take
place
vic
densiti
decreas
cell
express
alpha
smooth
muscl
actin
instead
vimentin
similarli
stimul
vic
vitro
result
fibroblast
vimentinhigh
myofibrolast
vimentinlow
transit
given
mesenchym
stem
cell
msc
exert
effect
investig
effect
condit
media
cm
deriv
canin
wharton
jelli
msc
growth
potenti
canin
vic
abil
counter
effect
vic
isol
cultur
normal
diseas
valv
immunohistochemistri
pcr
use
evalu
express
vimentin
elastin
collagen
vic
cm
collect
cultur
cm
exosom
isol
either
ultrafiltr
ultracentrifug
cell
growth
replic
capac
evalu
use
mtt
assay
coloni
form
unit
cfu
intern
exosom
vic
imag
membran
rna
stain
qpcr
show
diseas
valv
vic
increas
myofibroblast
phenotyp
decreas
cell
growth
mtt
cfu
cultur
vic
either
phenotyp
cm
exosom
alon
result
increas
number
viabl
cell
deplet
exosom
opposit
effect
exosom
membran
rna
label
confirm
exosom
uptak
vic
cytoplasm
nucleu
although
rna
contain
exosom
intern
vic
impli
select
endocytosi
rna
contain
exosom
less
numer
increas
respons
stimul
vic
cultur
cm
note
cm
exosom
improv
cell
growth
vic
isol
normal
diseas
canin
mitral
valv
may
exert
protect
effect
vic
slow
progress
canin
mmvd
joshua
eric
samantha
california
davi
school
veterinari
medicin
depart
medicin
epidemiolog
daiv
california
usa
arizona
colleg
medicin
depart
cellular
molecular
medicin
tucson
arizona
usa
coloni
mix
breed
cat
harbor
mutat
associ
develop
hypertroph
cardiomyopathi
hcm
main
coon
hcm
main
coon
cat
carri
mutat
cardiac
regulatori
protein
myosin
bind
protein
c
diseas
incomplet
penetr
hypothes
cardiac
biomark
reveal
inherit
pattern
cat
mutat
may
identifi
cat
risk
hcm
develop
earlier
echocardiographi
cat
genotyp
statu
echocardiographi
serum
ntprobnp
plasma
cardiac
ctni
analyz
cat
echocardiograph
diagnos
hcm
studi
homozyg
ho
heterozyg
het
wild
type
wt
cat
includ
median
age
wt
het
ho
cat
month
respect
median
iqr
biomark
calcul
group
compar
signific
differ
p
test
ctni
differ
group
ntprobnp
valu
follow
wt
het
ho
significantli
differ
genotyp
contrast
previou
studi
mutant
cat
signific
ntprobnp
elev
present
absenc
echocardiograph
diagnosi
hcm
ntprobnp
elev
follow
model
heterozyg
cat
less
sever
elev
homozyg
cat
match
previou
observ
clinic
character
diseas
context
incomplet
penetr
ntprobnp
may
repres
tool
earli
identif
hcm
affect
cat
jeffrey
thoma
evan
pierluca
medic
menlo
park
california
usa
institut
innov
mountain
view
california
usa
cardiovascular
wayn
new
jersey
usa
studi
evalu
safeti
myocardi
compress
requir
perform
epicardi
annuloplasti
biocompat
devic
ten
swine
seven
test
three
control
use
devic
place
subject
dimens
mitral
valv
reduc
echocardiographi
angiographi
perform
pre
implant
post
implant
term
test
devic
secur
test
group
remov
anim
control
group
necropsi
perform
day
heart
pressur
fix
analyz
test
devic
place
without
incid
coronari
flow
eject
fraction
left
ventricular
wall
motion
mitral
valv
anteroposterior
dimens
normal
post
implant
term
remark
postop
event
subject
surviv
term
except
one
test
anim
euthan
due
non
devic
relat
complic
refractori
pleural
effus
devic
well
toler
caus
minim
mild
fibrosi
chronic
inflamm
signific
chang
observ
myocardium
except
muscl
fiber
atrophi
near
tip
anterior
arm
appear
ampl
tissu
tip
danger
perfor
one
subject
meaning
chang
note
cardiac
shape
ventricular
wall
thick
chamber
size
heart
valv
blood
vessel
myocardi
compress
necessari
perform
epicardi
annuloplasti
well
toler
devic
safe
biocompat
colin
schwarzwald
iri
huesler
vetsuiss
faculti
univers
zurich
zurich
switzerland
echocardiograph
assess
left
atrial
la
size
routin
done
hors
varieti
convent
linear
novel
indic
la
size
describ
clinic
use
standard
novel
indic
poorli
establish
goal
studi
defin
refer
interv
indic
la
size
hors
provid
prove
concept
use
indic
la
size
speci
agreement
convent
linear
measur
novel
indic
la
size
assess
popul
healthi
hors
hors
valvular
regurgit
forti
healthi
hors
year
kg
hors
mitral
andor
aortic
insuffici
year
kg
includ
studi
echocardiograph
examin
perform
singl
oper
cc
use
standard
protocol
ge
vivid
dimens
maximum
la
diamet
measur
long
axi
view
ladmax
maximum
la
diamet
measur
long
axi
view
maximum
la
area
measur
long
axi
view
laamax
maximum
la
area
measur
short
axi
view
lasxamax
measur
oper
measur
allometr
scale
bodi
weight
kg
refer
interv
calcul
base
subpopul
healthi
warmblood
hors
refer
valu
advisor
method
agreement
investig
use
linear
regress
calcul
weight
kappa
analys
level
signific
studi
popul
healthi
diseas
hors
ladmax
refer
interv
cm
cm
mean
bia
limit
agreement
smaller
refer
interv
cm
significantli
relat
p
moder
agreement
classif
la
dimens
reduc
normal
increas
size
hors
ladmax
within
normal
limit
normal
convers
hors
within
normal
limit
ladmax
normal
laamax
refer
interv
smaller
lasxamax
refer
interv
significantli
relat
p
ladmax
significantli
associ
laamax
p
lasxamax
p
respect
howev
hors
ladmax
within
normal
limit
diagnos
enlarg
la
base
laamax
enlarg
la
base
lasxamax
hors
ladmax
within
normal
limit
enlarg
la
base
laamax
enlarg
la
base
lasxamax
respect
hors
laamax
lasxamax
within
normal
limit
enlarg
ladmax
enlarg
method
agreement
laamax
lasxamax
fair
hors
laamax
within
normal
limit
lasxamax
normal
convers
hors
lasxamax
within
normal
limit
laamax
normal
conclus
linear
measur
measur
la
size
alway
good
agreement
therefor
la
enlarg
diagnos
base
singl
measur
instead
multipl
measur
la
size
includ
linear
variabl
obtain
complement
subject
assess
la
dimens
clinic
patient
jessica
greg
sandra
bruce
teresa
state
univers
colleg
veterinari
medicin
raleigh
north
california
usa
countri
veterinari
specialist
fastvettm
san
antonio
texa
usa
lung
ultrasound
lu
emerg
imag
techniqu
suggest
presenc
cardiogen
pulmonari
edema
chf
identifi
ultrasound
artifact
caus
interstiti
alveolar
fluid
studi
design
determin
accuraci
protocol
lu
techniqu
diagnos
chf
dyspneic
dog
cat
dog
cat
enrol
evalu
acut
dyspnea
exclus
criteria
includ
trauma
pleural
effus
lack
thorac
radiograph
within
hour
lu
patient
underw
lu
quantifi
presenc
site
hemithorax
individu
site
score
posit
observ
lu
posit
site
hemithorax
consid
posit
chf
medic
record
evalu
final
diagnosi
patient
chf
higher
number
differ
distribut
posit
lu
site
compar
patient
noncardiac
diseas
sensit
specif
lu
diagnos
chf
respect
consid
cat
sensit
specif
lu
respect
diagnost
accuraci
lu
similar
thorac
radiograph
lu
tend
misdiagnos
chf
case
diffus
interstitialalveolar
diseas
ard
variabl
quantif
low
kappa
statist
conclus
lu
use
predict
chf
caus
dyspnea
particularli
cat
consid
util
rapid
techniqu
lu
consid
diagnost
tool
dyspneic
veterinari
patient
rebecca
virginia
lui
heidi
wisconsin
school
veterinari
medicin
madison
wisconsin
usa
veterinari
colleg
london
uk
systol
heart
murmur
whippet
may
due
myxomat
mitral
valv
diseas
mmvd
may
unassoci
structur
heart
diseas
hd
echocardiographi
echo
may
requir
differenti
mmvd
function
murmur
screen
program
alway
avail
pilot
studi
compar
abil
bnp
ctni
concentr
versu
auscult
predict
hd
cohort
outwardli
healthi
whippet
screen
nation
show
one
hundr
thirti
five
dog
underw
auscult
echo
blood
sampl
bnp
ctni
analysi
echo
result
review
identifi
presenc
hd
base
presenc
follow
mitral
valv
prolaps
mitral
regurgit
left
atrialventricular
dilat
presenc
ventricular
prematur
complex
echo
exam
categor
echo
neg
posit
echo
evid
hd
blood
test
result
analyz
p
dog
group
n
dog
heart
murmur
n
bnp
express
pmoll
ctni
nmolml
echo
preval
popul
dog
systol
murmur
mur
left
basilar
lb
left
apic
la
echo
preval
mur
dog
median
bnp
higher
dog
la
rang
p
versu
murmur
lb
bnp
higher
echo
dog
n
versu
n
p
mur
dog
bnp
significantli
higher
echo
dog
n
versu
n
p
median
ctni
higher
la
dog
p
versu
murmur
lb
ctni
higher
echo
dog
n
versu
n
p
mur
dog
ctni
higher
echo
dog
versu
p
roc
analysi
use
predict
diagnost
valu
bnp
ctni
test
characterist
report
result
pilot
studi
suggest
absenc
auscult
bnp
ctni
may
use
distinguish
whippet
hd
without
hd
murmur
statu
known
ppv
test
improv
simon
ivan
amara
ashley
curt
veterinari
medicin
gainesvil
florida
usa
heart
center
gainesvil
florida
usa
canin
valvular
pulmon
stenosi
categor
base
degre
leaflet
thicken
leaflet
fusion
pulmonari
arteri
hypoplasia
dog
mild
moder
diseas
normal
life
expect
sever
diseas
die
prematur
balloon
dilat
often
success
sever
case
thin
fuse
leaflet
result
decreas
clinic
sign
increas
life
expect
dog
thicken
dysplast
valv
pulmonari
arteri
hypoplasia
show
limit
respons
balloon
dilat
two
case
report
describ
use
stent
treat
obstruct
pulmonari
blood
flow
dog
one
dog
supravalvular
stenosi
treat
success
stent
second
dog
sever
dysplast
pulmonari
valv
stenosi
initi
well
stenosi
recur
within
month
describ
use
bare
metal
stent
treat
sever
dysplast
pulmonari
valv
stenosi
dog
dog
initi
singl
stent
implant
good
reduct
pressur
gradient
maintain
long
term
dog
one
dog
suffer
stent
fractur
result
stent
embol
dog
subsequ
underw
repeat
cardiac
catheter
four
addit
stent
place
right
ventricular
outflow
tract
treat
sever
dynam
subvalvular
pulmon
stenosi
dog
continu
receiv
atenolol
clopidogrel
find
suggest
select
patient
stent
sever
dysplast
pulmonari
valv
stenosi
viabl
option
provid
long
term
relief
obstruct
loi
virginia
lui
mark
royal
veterinari
colleg
hatfield
hertfordshir
uk
univers
ithaca
new
york
usa
aim
investig
agreement
echocardiograph
classif
cardiomyopathi
cat
onlin
survey
devis
video
loop
still
imag
echocardiograph
record
compil
cat
rang
cardiac
phenotyp
signal
brief
clinic
histori
provid
survey
distribut
via
veterinari
inform
network
vin
member
cardiolog
list
serv
list
possibl
diagnos
provid
particip
ask
indic
describ
case
accur
select
multipl
diagnos
allow
respond
ask
includ
brief
justif
choic
agreement
assess
repeat
case
fleiss
kappa
calcul
particip
complet
respons
determin
inter
agreement
order
assess
whether
agreement
greater
among
cardiologist
agreement
also
calcul
use
respons
acvim
ecvim
diplom
survey
attempt
particip
routin
involv
echocardiograph
assess
cat
myocardi
diseas
particip
clinic
experi
veterinari
cardiolog
rang
month
year
acvim
diplom
ecvim
diplom
case
score
perfect
inter
agreement
overal
agreement
rang
depend
case
agreement
among
acvimecvim
diplom
agreement
agreement
observ
rang
fleiss
kappa
valu
demonstr
classif
cat
cardiomyopathi
inconsist
particip
suggest
differ
criteria
may
use
agreement
also
poor
suggest
irrespect
diagnost
criteria
use
inconsist
appli
agreement
might
improv
standard
echocardiograph
criteria
use
diagnos
differ
cardiomyopathi
phenotyp
kieran
stijn
christoph
ruth
sophi
julia
patrick
yaiza
david
virginia
lui
david
veterinari
colleg
london
uk
veterinari
referr
bristol
uk
human
hypersomatotrop
caus
function
pituitari
mass
recogn
caus
increas
left
ventricular
lv
mass
cardiovascular
complic
major
caus
morbid
mortal
hypothes
felin
hypersomatotrop
associ
increas
lv
wall
thick
left
atrial
la
dilat
compar
control
group
diabet
healthi
cat
cat
confirm
hypersomatotrop
ngml
pituitari
mass
n
prospect
recruit
two
control
group
diabet
cat
ngml
n
healthi
cat
histori
diabet
cardiovascular
diseas
n
cat
endocrinopathi
exclud
echocardiographi
perform
case
studi
measur
one
train
oper
normal
distribut
continu
variabl
compar
use
anova
distribut
variabl
compar
use
test
categor
data
compar
use
test
pair
data
compar
use
wilcoxon
sign
rank
test
signific
p
correct
pairwis
comparison
age
differ
group
p
cat
hypersomatotrop
greater
maximum
lv
wall
thick
mm
mm
diabet
mm
mm
p
normal
cat
mm
mm
p
la
diamet
greater
cat
hypersomatotrop
mm
mm
diabet
mm
mm
p
healthi
cat
mm
mm
p
aortic
insuffici
common
cat
hypersomatotrop
diabet
normal
cat
p
hypophysectomi
n
echocardiograph
chang
mostli
revers
figur
hypersomatotrop
natur
occur
revers
caus
lv
hypertrophi
la
dilat
cat
lanc
visser
minu
im
joshua
stern
depart
medicin
epidemiolog
school
veterinari
medicin
univers
california
davi
davi
california
usa
sought
determin
valu
right
pulmonari
arteri
distens
index
rpadi
predict
estim
systol
pulmonari
arteri
pressur
spap
dog
pulmonari
hypertens
ph
compar
echocardiograph
indic
ph
dog
tricuspid
regurgit
tr
permit
estim
spap
prospect
recruit
group
control
n
spap
mmhg
dog
mild
n
spap
mmhg
moder
n
spap
mmhg
sever
n
spap
mmhg
ph
indic
ph
quantifi
rpadi
percent
chang
diamet
pa
systol
diastol
pulmonari
diamet
pa
ao
acceler
time
peak
pa
flow
veloc
time
pa
flow
et
associ
indic
ph
spap
right
ventricular
fraction
area
chang
fac
age
gender
heart
rate
bodi
weight
perform
use
linear
regress
receiv
oper
characterist
analysi
perform
determin
optim
cutoff
valu
indic
ph
predict
moder
increas
spap
mmhg
rpadi
r
show
strongest
correl
spap
follow
pa
ao
r
et
r
fac
r
weakli
r
correl
heart
rate
signific
correl
identifi
cutoff
predict
moder
ph
defin
rpadi
sensit
sn
specif
sp
et
sn
sp
ms
sn
sp
pa
ao
sn
sp
rpadi
may
use
predict
ph
dog
tr
absent
c
elizabeth
nasser
padmanabh
xiaoyang
brian
gwendolyn
joseph
ami
jonathan
veterinari
medicin
biomed
scienc
texa
univers
colleg
station
texa
usa
texa
md
anderson
cancer
center
houston
texa
usa
therapeut
san
diego
california
usa
signal
transduc
activ
transcript
pathway
key
regul
tumorigenesi
immun
suppress
microrna
mir
shown
inhibitor
signal
rodent
model
glioma
system
administr
design
result
immun
effector
respons
tumor
regress
enhanc
surviv
addit
revers
immun
suppress
anergi
immun
cell
human
glioblastoma
patient
investig
express
level
canin
astrocytoma
n
normal
brain
n
determin
tumor
share
key
biolog
featur
human
rodent
glioma
found
express
absent
increas
canin
glioma
rel
normal
brain
level
express
number
cell
directli
correl
astrocyt
grade
next
investig
safeti
pharmacokinet
healthi
dog
n
signific
advers
event
toxic
note
escal
sustain
dose
induc
vivo
immun
effector
respons
detect
flow
cytometri
pharmacokinet
studi
confirm
deliveri
immun
compart
intraven
administr
cumul
data
indic
oper
therapeut
target
canin
glioma
system
administr
safe
feasibl
initi
phase
iii
clinic
trial
canin
spontan
aris
glioma
ascertain
induc
radiograph
regress
prolong
surviv
rebecca
packer
stephani
engel
colleg
veterinari
medicin
biomed
scienc
colorado
state
univers
fort
collin
colorado
usa
studi
describ
surgic
techniqu
tissu
resect
devic
link
neuronavig
system
direct
onscreen
guidanc
brain
tumor
excis
techniqu
consid
first
step
toward
guid
neurosurgeri
excis
otherwis
inaccess
deep
intraaxi
tumor
goal
studi
improv
access
deep
poorli
access
mass
reduc
surgic
trauma
use
target
approach
improv
resect
tool
retrospect
evalu
dog
cat
underw
brain
tumor
excis
use
myriad
nico
corpor
brainsight
neuronavig
system
rogu
research
perform
patient
resect
instrument
regist
neuronavig
system
surgeri
guid
onscreen
visual
resect
instrument
posit
rel
mri
imag
direct
visual
possibl
case
degre
resect
evalu
mri
resect
gtr
residu
tumor
evid
resect
ntr
resect
resect
str
resect
case
achiev
gtr
equivoc
achiev
ntr
achiev
str
resect
cortic
subcort
brain
tumor
use
myriad
feasibl
studi
goal
achiev
part
refin
requir
studi
adapt
techniqu
surgic
approach
deep
brain
tumor
resect
improv
visibl
minim
effect
brain
shift
impact
clinic
outcom
approach
must
also
determin
rachel
song
maureen
oldach
ronaldo
da
costa
sarah
moor
ohio
state
univers
columbu
ohio
usa
util
finger
paint
techniqu
walk
track
analysi
evalu
control
dog
dog
acut
thoracolumbar
spinal
cord
injuri
sci
caus
spontan
intervertebr
disc
extrus
ivd
stride
length
sl
bs
cov
paramet
measur
four
limb
three
separ
time
point
normal
dog
day
follow
laminectomi
dog
sci
sl
bs
compar
control
dog
time
point
recoveri
p
consid
statist
signific
differ
mean
sl
cm
control
dog
left
thorac
limb
tl
right
tl
left
pelvic
limb
pl
right
pl
respect
four
limb
control
dog
mean
sl
four
limb
significantli
shorter
dog
day
compar
normal
dog
mean
differ
sl
normal
dog
declin
significantli
time
recoveri
injuri
cm
significantli
wider
dog
compar
control
day
surgeri
cm
differ
group
find
support
util
simplifi
method
walk
track
analysi
compar
differ
pelvic
limb
sl
normal
dog
assess
chang
sl
marker
recoveri
sci
susan
henni
van
den
eric
roberto
la
clare
surrey
guildford
uk
den
heuvel
best
netherland
malform
cm
syringomyelia
sm
complex
inherit
disord
observ
commonli
toy
breed
dog
caus
signific
loss
qualiti
life
though
pain
disabl
brachycephalic
risk
factor
suggest
crossbreed
differ
breed
backcross
may
produc
individu
free
diseas
two
half
year
project
took
advantag
cross
mesaticephal
normal
australian
terrier
cm
affect
griffon
bruxelloi
gb
subsequ
backcross
gb
investig
inherit
phenotyp
condit
mean
reduc
incid
cm
risk
sm
studi
cohort
compris
control
dog
cm
affect
australian
terrier
unrel
gb
without
cm
singl
famili
dog
use
differ
mate
combin
result
progeni
sagitt
dicom
imag
analyz
trait
angl
line
best
fit
circl
diamet
shown
previous
greatest
signific
cm
gb
quantit
find
studi
reveal
trait
signific
furthermor
extern
phenotyp
show
outcross
breed
type
select
appropri
conform
characterist
gener
possibl
regain
gb
breed
standard
gener
reduc
degre
cm
howev
depend
care
select
conform
screen
cm
sm
year
age
dog
affect
sm
studi
exhibit
reduc
caudal
skull
develop
compar
rel
show
trait
mr
imag
use
distinguish
phenotyp
exhibit
segreg
may
addit
toward
sever
cm
suggest
trait
might
use
quantifi
condit
risk
sm
propos
grade
cm
take
account
quantit
trait
use
estim
breed
valu
ebv
assist
breeder
mate
select
system
verifi
ensur
appropri
breed
risk
peter
dickinson
daniel
york
robert
higgin
richard
lecouteur
danika
bannasch
uc
davi
school
veterinari
medicin
davi
california
usa
defin
commonli
occur
cytogenet
abnorm
canin
glioma
essenti
understand
gliomagenesi
definit
appropri
therapeut
strategi
use
illumina
hd
snp
array
determin
copi
number
alter
allel
imbal
histolog
confirm
spontan
canin
glioma
astrocytoma
oligodendroglioma
mix
oligoastrocytoma
cell
line
copi
number
call
allel
event
determin
match
pair
analysi
use
biodiscoveri
nexu
copi
softwar
hierarch
cluster
aberr
profil
reveal
two
major
group
glioblastoma
grade
ii
astrocytoma
compris
one
group
compar
analysi
show
loss
locu
tumor
suppressor
gene
significantli
associ
glioblastoma
queri
aberr
event
specifi
gene
show
common
lossesloss
heterozygos
tumor
suppressor
gene
amplif
oncogen
pathway
specif
loss
gain
present
pathway
loss
present
pathway
loss
pten
gain
pdgfra
present
pathway
evalu
oligodendroglioma
delet
synten
commonli
describ
loss
human
oligodendroglioma
reveal
synten
loss
cfa
canin
tumor
preliminari
data
suggest
canin
glioma
pathway
alter
common
human
tumor
counterpart
howev
definit
pathway
greater
detail
warrant
inform
appropri
choic
target
therapi
interpret
futur
therapeut
trial
r
timothi
aaron
david
deborah
veterinari
medicin
west
lafayett
indiana
usa
univers
indianapoli
indiana
usa
glioma
dog
typic
fatal
limit
inform
avail
guid
therapi
spontan
brain
tumor
dog
suggest
translat
model
develop
human
therapi
chlorambucil
report
display
neglig
penetr
normal
anim
penetr
investig
purpos
translat
studi
perform
safeti
pharmacokinet
studi
metronom
chlorambucil
chemotherapi
dog
glioma
four
dog
glioma
began
receiv
metronom
chlorambucil
po
q
hour
underw
surgic
resect
chlorambucil
concentr
serum
cerebrospin
fluid
surgic
brain
tumor
specimen
analyz
patient
addit
receiv
ccnu
monitor
monthli
examin
laboratori
work
repeat
magnet
reson
imag
perform
one
patient
suffer
cerebrovascular
accid
two
current
complet
remiss
fourth
euthan
month
brain
tumor
harvest
repeat
chlorambucil
concentr
analysi
increas
seizur
observ
cytopenia
major
chemotherapi
complic
detect
brain
tumor
chlorambucil
concentr
rang
limit
quantif
ngspecimen
well
excess
serum
concentr
patient
indic
variabl
penetr
chlorambucil
could
gener
detect
cerebrospin
fluid
metronom
chlorambucil
chemotherapi
well
toler
dog
glioma
may
penetr
individu
case
preliminari
evid
activ
mario
dolera
luca
malfassi
simon
pavesi
massimo
sala
giovanni
mazza
silvia
marcarini
nanci
carrara
sara
finesso
la
cittadina
fondazion
studi
e
ricerch
veterinari
romanengo
itali
updat
canin
peripher
nerv
sheath
tumor
pnst
appear
recent
literatur
aim
studi
evalu
correl
clinic
aspect
mri
find
tumor
involv
major
peripher
nerv
plexu
root
determin
surviv
time
dog
treat
palliat
surgeri
stereotact
radiotherapi
srt
record
dog
pnst
evalu
review
determin
signal
durat
clinic
sign
neurolog
examin
mri
featur
treatment
option
palliat
surgeri
stereotact
hypo
fraction
radiotherapi
time
first
event
surviv
time
statist
differ
across
categori
calcul
product
limit
method
test
dog
median
age
year
male
femal
ratio
includ
labrador
retrieveroverrepres
root
lesion
frequent
v
nerv
left
side
involv
present
sing
lame
paresi
pain
mean
durat
clinic
sign
day
mri
find
compris
increas
diamet
hyper
intens
contrast
enhanc
nerv
root
plexu
peripher
nerv
focal
hypomiotropi
muscl
hyper
intens
time
first
event
day
surgeri
day
srt
overal
mean
surviv
day
palliat
surgeri
srt
predilect
labrador
retriev
observ
compar
result
publish
data
srt
seem
promis
better
result
palliat
surgeri
warrant
evalu
mario
dolera
luca
malfassi
roberto
vailati
facchini
sara
finesso
giovanni
mazza
la
cittadina
fondazion
studi
e
ricerch
veterinari
romanengo
itali
aim
studi
document
pheripher
glycaemia
variat
hypoperfus
limb
patient
affect
magnet
reson
imag
mri
arteri
thrombosi
eleven
dog
recruit
inclus
criteria
clinic
examin
support
limb
hypoperfus
avail
blood
cell
count
biochem
profil
urin
analys
two
blood
sampl
sampl
one
affect
limb
one
healti
limb
plasmat
glycaemia
measur
use
autom
glucos
analys
patient
underw
total
bodi
mri
provid
final
diagnosi
thrombu
locat
abdomin
aorta
subclavian
arteri
axillari
arteri
iliac
arteri
total
abdomin
aortic
thrombosi
involv
also
intern
iliac
arteri
extern
one
extent
thrombosi
classifi
grade
greatest
portion
thrombu
reach
half
vessel
lumen
grade
greatest
portion
thrombu
vessel
lumen
grade
thrombu
exced
lumen
substanti
decreas
pheripher
glycaemia
valu
found
sampl
aris
affect
limb
compar
affect
limb
valu
healthi
limb
measur
patient
reduct
found
account
grade
score
patient
percentag
reduct
found
mario
dolera
luca
malfassi
simon
pavesi
massimo
sala
giovanni
mazza
silvia
marcarini
nanci
carrara
la
cittadina
fondazion
studi
e
ricerch
veterinari
romanengo
itali
surgic
stabil
canin
lumbosacr
spine
challeng
aim
research
evalu
two
surgic
techniqu
achiev
lumbosacr
stabil
dog
either
normal
transit
vertebra
lumbosacr
instabl
degen
stenosi
evalu
dynam
comput
tomographi
ct
magnet
reson
imag
mri
dog
normal
vertebra
two
mm
screw
bicort
insert
head
behind
caudal
articular
process
prevent
extens
lumbosacr
joint
ventral
listhesi
evid
head
screw
augment
methyl
methacryl
dog
transit
vertebra
two
mm
screw
insert
iliac
wing
two
mm
screw
insert
spinou
process
emerg
screw
embed
methyl
methacryl
flexion
lombosacr
spine
case
residu
radicular
compress
dorsal
laminectomi
partial
discectomi
accomplish
serial
clinic
imag
follow
examin
perform
larg
breed
dog
enrol
dog
augment
dog
iliac
wing
screw
insert
dog
requir
addit
decompress
mean
follow
month
clinic
examin
imag
reveal
amelior
present
complaint
reduct
radicular
compress
surgic
complic
iliac
wing
techniqu
effect
method
obtain
stabil
indirect
decompress
lumbosacr
joint
compar
describ
surgic
procedur
obtain
result
better
lesser
complic
fred
nichola
stephen
specialti
servic
st
loui
missouri
usa
missouri
columbia
missouri
usa
research
montreal
quebec
canada
multipl
patholog
dog
spine
requir
stabil
vertebr
implant
optim
implant
corridor
describ
vari
specif
vertebra
throughout
spine
current
placement
guidelin
use
gener
surfac
landmark
propos
angl
without
opportun
visual
vital
structur
depth
prefer
corridor
often
inaccess
soft
tissu
impedi
potenti
complic
vertebr
implant
placement
includ
compromis
insuffici
bone
purchas
requir
biomechan
load
implant
present
ad
challeng
align
vertebr
motion
unit
counter
biomechan
stress
recent
report
suggest
frequenc
spinal
canal
violat
vertebr
implant
high
frameless
stereotaxi
brain
neuronavig
describ
veterinari
literatur
valid
studi
show
high
level
accuraci
techniqu
util
high
resolut
cross
section
imag
creat
data
set
identif
fiduci
marker
visibl
model
imag
space
subject
intraop
anatom
space
permit
fusion
guidanc
posit
sensor
use
track
reflect
instrument
affix
skull
surgic
tool
within
virtual
space
surgeon
identifi
point
within
virtual
space
tissu
sampl
treatment
purpos
studi
develop
techniqu
implant
placement
dog
spine
use
intervent
unlik
brain
encas
within
solid
calvarium
regist
navig
softwar
structur
reliabl
identifi
rel
origin
coordin
system
two
major
obstacl
consid
neuronavig
vertebr
column
first
multipl
vertebr
motion
unit
requir
individu
registr
vertebr
column
made
multipl
articul
bone
make
singl
bone
registr
inapplic
remain
vertebra
novel
subject
tracker
creat
attach
singl
vertebra
individu
registr
second
obstacl
adapt
frameless
neuronavig
spine
assign
fiduci
marker
current
brain
protocol
requir
procedur
placement
artifici
fiduci
maker
rigidli
affix
skull
teeth
surgeri
affix
fiduci
array
logist
difficult
spinal
applic
reason
identif
natur
boney
fiduci
marker
identifi
imag
anatom
space
prefer
evalu
landmark
includ
spinou
process
accessori
process
cranial
costovertebr
joint
initi
cadaver
studi
valid
techniqu
thoracolumbar
spine
perform
qualit
measur
canal
compromis
bone
purchas
addit
quantit
measur
trajectori
depth
evalu
safeti
efficaci
find
zero
canal
violat
statist
accur
placement
mostli
implant
warrant
clinic
use
complet
clinic
case
includ
three
thoracolumbar
fractur
vertebr
bodi
screw
two
atlantoaxi
stabil
three
lumbosacr
stabil
transarticular
screw
stereotact
guidanc
enabl
surgeon
visual
implant
real
time
case
imag
adequ
placement
implant
satisfactori
clinic
outcom
describ
adapt
provid
mean
safe
effect
placement
vertebr
implant
multipl
trajectori
could
creat
computer
guidanc
subject
less
soft
tissu
dissect
necessari
surgic
time
minim
extend
roger
clemmon
univers
florida
gainesvil
florida
usa
implant
use
help
treat
epilepsi
interfer
modern
imag
techniqu
like
mri
examin
polylact
acid
pla
biodegrad
implant
plastic
appear
offer
similar
effect
gold
materi
degrad
time
invis
modern
imag
purpos
studi
investig
whether
pla
bead
disc
mm
mm
could
use
assist
control
refractori
epilepsi
dog
place
specif
acupunctur
point
thought
affect
seizur
descript
studi
case
seri
done
preliminari
studi
ten
patient
present
univers
florida
neurolog
servic
experienc
frequent
seizur
refractori
anticonvuls
medic
enrol
studi
patient
system
evalu
demonstr
signific
find
mri
evalu
demonstr
signific
chang
central
nervou
system
csf
analysi
reveal
abnorm
mani
patient
experienc
cluster
seizur
requir
emerg
intervent
control
seizur
adjust
medic
made
studi
although
anticonvuls
could
reduc
pla
bead
treatment
given
eeg
perform
dog
pla
bead
placement
analyz
statist
packag
neurostat
packag
neuroguid
appli
neurosci
inc
seminol
fl
pla
bead
place
transposit
classic
acupunctur
point
certifi
veterinari
acupuncturist
chi
institut
reddick
fl
inject
site
wipe
ethyl
alcohol
gel
purel
advanc
hand
sanit
gojo
industri
akron
oh
pla
bead
insert
use
modifi
ga
needl
syring
point
use
long
hui
nao
shu
shen
tian
ping
bai
hui
auricular
point
shen
men
owner
ask
keep
calendar
seizur
event
comparison
seizur
frequenc
data
compar
test
anova
use
statist
program
spss
ver
ten
patient
enrol
studi
deem
satisfactori
result
owner
patient
show
reduct
seizur
moreov
seizur
characterist
chang
seizur
like
singular
rather
multipl
p
patient
respond
euthan
owner
seizur
occur
week
bead
placement
later
recogn
period
time
patient
like
seizur
specul
consequ
heal
implant
procedur
bead
took
protect
one
patient
sever
cluster
everi
day
prior
bead
implant
remain
seizur
free
year
use
bead
everi
month
preliminari
investig
found
bead
implant
last
month
averag
patient
everi
month
base
upon
owner
desir
eeg
examin
patient
prior
implant
show
activ
occasion
epileptiform
discharg
spike
activ
frequent
wave
form
enhanc
alpha
wave
pattern
follow
bead
implant
signific
reduct
amplitud
eeg
activ
p
pla
bead
placement
specif
point
around
head
acupunctur
point
found
reduc
seizur
appear
significantli
reduc
seizur
activ
refractori
epilept
patient
also
evid
acut
reduct
electr
activ
cortex
base
upon
chang
eeg
follow
bead
implant
may
repres
promis
new
method
help
control
refractori
seizur
dog
g
dian
shelton
univers
california
san
diego
la
jolla
california
usa
past
year
sever
inherit
myopathi
report
young
labrador
retriev
distinct
clinic
phenotyp
easili
recogn
other
requir
depth
examin
includ
state
art
evalu
muscl
biopsi
dna
test
report
describ
current
statu
inherit
myopathi
labrador
retriev
breed
guid
clinic
recognit
earli
onset
sever
gener
muscl
weak
occur
first
sever
week
life
describ
congenit
myasthen
syndrom
associ
autosom
recess
mutat
colq
encod
collagen
tail
acetylcholinesteras
weak
disord
fatig
anticholinesteras
drug
exacerb
weak
sever
gener
progress
weak
also
describ
myotubular
myopathi
associ
mutat
lipid
phosphatas
disord
creatin
kinas
ck
activ
normal
minim
elev
anoth
potenti
sever
myopathi
occur
age
group
dystrophin
defici
muscular
dystrophi
xlmd
key
find
markedli
persist
elev
ck
activ
find
along
dystroph
phenotyp
muscl
biopsi
help
distinguish
sever
myopathi
congenit
myopathi
less
sever
myopathi
occur
sever
month
age
includ
autosom
recess
centronuclear
myopathi
associ
mutat
ptpla
clinic
present
appear
similar
myotubular
myopathi
howev
rapidli
progress
affect
dog
live
well
adulthood
ck
activ
normal
mildli
elev
muscl
biopsi
show
myopath
phenotyp
numer
central
nuclei
mild
form
xlmd
recent
identifi
sever
relat
male
labrador
retriev
markedli
elev
ck
activ
detect
time
neuter
clinic
evid
weak
muscl
atrophi
observ
muscl
biopsi
show
dystroph
phenotyp
dystrophin
detect
western
blot
protect
dog
devast
effect
dystrophin
defici
yet
determin
myopathi
progress
gait
abnorm
multipl
joint
deform
recent
identifi
associ
sarcolemm
specif
collagen
vi
defici
similar
human
ulrich
congenit
muscular
dystrophi
mutat
confirm
yet
publish
although
myopathi
syndrom
collaps
character
mutat
cn
specif
gene
describ
dog
syndrom
clinic
normal
appear
activ
help
separ
disord
character
inherit
myopathi
summari
mani
inherit
myopathi
describ
young
labrador
retriev
dog
clinician
need
awar
specif
phenotyp
knowledg
myopath
disord
recognit
myopath
phenotyp
enabl
precis
clinic
diagnosi
guid
breeder
elimin
disord
line
denni
tendai
gayl
dian
jeremi
nicola
jeremi
robert
gari
missouri
columbia
missouri
usa
california
san
diego
san
diego
california
usa
bristol
langford
north
somerset
uk
juvenil
onset
laryng
paralysispolyneuropathi
report
black
russian
terrier
brt
purpos
studi
character
phenotyp
identifi
mutat
respons
three
brt
laryng
paralysi
weak
examin
univers
missouri
mu
underw
electrodiagnost
test
medic
record
brt
review
histopatholog
examin
dog
whole
genom
sequenc
wg
perform
one
affect
brt
rare
homozyg
variant
ascertain
comparison
canid
wg
affect
brt
present
month
age
laryng
paresisparalysi
mu
case
miotic
pupil
cataract
microphthalmia
andor
persist
pupillari
membran
neurolog
examin
show
sensori
motor
deficit
electromyogram
show
prolong
insert
activ
fibril
complex
repetit
discharg
tibial
nerv
studi
show
moder
reduc
conduct
veloc
compound
motor
unit
action
potenti
amplitud
muscl
nerv
patholog
promin
larynx
consist
neurogen
pattern
muscl
fiber
atrophi
decreas
densiti
larg
myelin
fiber
inappropri
thin
myelin
sheath
intraneuron
vacuol
found
cerebellar
roof
nuclei
purkinj
cell
wg
identifi
uniqu
homozyg
singl
base
pair
delet
produc
frame
shift
predict
prematur
stop
codon
truncat
gene
product
miss
amino
acid
dna
avail
affect
brt
homozyg
variant
normal
brt
either
heterozyg
homozyg
allel
mutat
caus
similar
phenotyp
human
warburg
micro
syndrom
denni
ana
rebecca
stephani
jeremi
robert
jason
laura
gari
missouri
columbia
missouri
usa
state
univers
fort
collin
colorado
usa
univers
west
lafayett
indiana
usa
specialti
center
yonker
new
york
usa
coast
veterinari
neurolog
seurosurgeri
houston
texa
usa
purpos
studi
character
hereditari
paroxysm
dyskinesia
soft
coat
wheaten
terrier
scwt
identifi
respons
mutat
medic
record
video
review
scwt
scwtpoodl
cross
present
movement
disord
whole
genom
sequenc
wg
perform
affect
scwt
rare
homozyg
variant
ascertain
comparison
canid
wg
affect
dog
episod
dystonia
andor
rapid
irregular
involuntari
movement
limb
typic
began
month
year
age
episod
last
minut
sever
hour
becam
frequent
sever
time
occur
dog
awak
dog
show
clear
trigger
benzodiazepin
antiepilept
drug
muscl
relax
show
limit
benefit
five
dog
treat
acetazolamid
improv
complet
resolut
dyskinesia
histopatholog
two
dog
show
patholog
wg
identifi
homozyg
pign
variant
affect
scwt
affect
scwt
cross
homozyg
variant
normal
scwt
either
heterozyg
homozyg
allel
randomli
select
poodl
dog
breed
homozyg
allel
pign
code
phosphatidylinositol
enzym
involv
synthesi
gpi
gpi
anchor
numer
protein
lipid
raft
cell
membran
includ
carbon
anhydras
mutat
pign
human
caus
syndrom
character
congenit
abnorm
neonat
hypotonia
seizur
choreoathetosi
junyoung
chulhyun
dongwoo
nation
univers
cheongju
korea
basic
scienc
institut
ochang
korea
nation
univers
jinju
korea
intracerebr
hemorrhag
ich
subtyp
stroke
high
mortal
disabl
effect
ich
upon
brain
tissu
biphas
includ
primari
secondari
injuri
although
hematoma
volum
main
factor
influenc
ich
outcom
secondari
brain
injuri
result
sever
neurolog
deficit
therefor
purpos
studi
investig
mechan
secondari
neuron
injuri
evalu
cerebr
blood
flow
cbf
metabolit
patholog
chang
around
intracerebr
hematoma
ich
induc
healthi
laboratori
beagl
dog
inject
u
bacteri
collagenas
clostridium
histolyticum
deliv
pariet
lobe
minut
micro
infus
pump
magnet
reson
imag
proton
mr
spectroscopi
mr
perform
serial
differ
time
point
use
mr
system
hour
day
ich
prussian
blue
immunohistochem
stain
perform
demonstr
iron
glial
fibrillari
acid
protein
gfap
tumor
necrosi
around
intracerebr
hematoma
hematoma
cerebr
blood
volum
cbv
significantli
decreas
day
ich
addit
signific
decreas
cbf
observ
day
ich
perihematoma
signific
chang
cbv
cbf
except
decreas
cbv
day
ich
proton
mr
reveal
abnorm
level
lactat
perihematoma
signific
loss
gfap
immunoreact
note
hematoma
wherea
iron
deposit
express
significantli
increas
howev
patholog
immunohistochem
chang
observ
perihematoma
conclus
decreas
cbf
iron
overload
inflamm
may
contribut
injuri
could
provid
therapeut
target
ich
dog
stephani
anni
david
alecia
univers
west
lafayett
indiana
usa
state
univers
pullman
washington
usa
epilepsi
recurr
seizur
report
common
neurolog
condit
dog
epilept
dog
consid
pharmacoresist
one
medic
recent
lab
anim
literatur
addit
studi
human
literatur
show
hormon
melatonin
signific
effect
epilept
human
actual
significantli
lower
serum
melatonin
level
compar
unaffect
peopl
central
hypothesi
studi
serum
level
melatonin
lower
dog
seizur
normal
dog
aim
compar
mean
serum
melatonin
level
normal
dog
versu
dog
seizur
sixti
two
dog
enrol
studi
normal
dog
dog
seizur
sampl
done
daylight
hour
three
separ
time
point
hour
hour
hour
melatonin
level
measur
pgml
use
radioimmunosassay
mean
melatonin
valu
hour
normal
dog
pgml
respect
valu
dog
seizur
pgml
time
point
statist
signific
exist
mean
serum
melatonin
valu
either
group
three
time
point
conclus
notabl
differ
daytim
serum
melatonin
valu
normal
dog
versu
dog
seizur
dougla
thamm
barbara
rose
travi
laver
alex
pyuen
colorado
state
univers
fort
collin
colorado
usa
lymphoma
seriou
condit
remain
unmet
medic
need
human
dog
gold
complex
auranofin
util
human
therapeut
primarili
antirheumat
agent
limit
inform
use
dog
report
antiprolif
activ
observ
varieti
human
cell
line
includ
carcinoma
breast
head
neck
ovari
lung
varieti
hematopoiet
tumor
includ
lymphoma
put
antitumor
mechan
includ
inhibit
signal
induct
reactiv
oxygen
speci
via
thioredoxin
reductas
inhibit
dog
model
spontan
lymphoma
human
owe
strike
similar
biolog
gene
express
goal
current
studi
investig
antineoplast
effect
auranofin
panel
canin
cell
line
identifi
potenti
biomark
drug
activ
futur
translat
studi
four
canin
lymphoma
cell
line
incub
vari
concentr
auranofin
bortezomib
elesclomol
convent
antineoplast
agent
doxorubicin
dox
ccnu
vincristin
vcr
hour
rel
viabl
cell
number
assess
use
mt
cell
cycl
distribut
apoptosi
induct
evalu
use
flow
cytometri
propidium
iodid
stain
annexin
v
pi
stain
respect
induct
ro
assess
use
fluoresc
dye
trxr
activ
assess
use
commerci
colorimetr
kit
cayman
chang
phosphoryl
statu
assess
via
western
analysi
auranofin
induc
antiprolif
effect
canin
lymphoma
cell
line
inhibitori
concentr
similar
observ
human
hematopoiet
tumor
cell
well
within
clinic
achiev
serum
concentr
apoptosi
induct
observ
addit
synergist
antiproliferativepropaptot
activ
observ
bortezomib
elesclomol
dox
ccnu
vcr
induct
ro
inhibit
trxr
activ
observ
follow
auranofin
treatment
antiprolif
activ
could
partial
block
scaveng
chang
phosphoryl
follow
auranofin
treatment
conclus
antitumor
activ
observ
auranofin
treatment
vitro
canin
lymphoma
cell
pharmacolog
achiev
concentr
similar
activ
observ
human
lymphoma
leukemia
cooper
activ
observ
target
agent
bortezomib
elesclomol
data
support
clinic
evalu
auranofin
canin
lymphoma
measur
ro
accumul
andor
trxr
activ
may
use
pharmacodynam
marker
drug
activ
dougla
michel
craig
kristin
corey
david
cheryl
state
univers
fort
collin
colorado
usa
veterinari
specialist
malvern
pennsylvania
usa
univers
north
grafton
massachusett
usa
georgia
athen
georgia
usa
wisconsin
madison
madison
wisconsin
usa
ohio
state
univers
columbu
ohio
usa
lymphoma
one
common
canin
cancer
current
therapi
induc
remiss
dog
lymphoma
relaps
common
distinct
need
novel
agent
acycl
nucleotid
phosphon
pmeg
form
activ
phosphoryl
metabolit
pmegpp
cell
caus
cytotox
divid
cell
due
inhibit
dna
polymeras
howev
pmeg
use
anticanc
agent
limit
poor
cellular
permeabl
nonspecif
toxic
rabacfosadin
novel
doubl
prodrug
pmeg
design
preferenti
target
lymphoid
cell
significantli
reduc
system
toxic
rabacfosadin
administ
varieti
dose
schedul
dog
lymphoma
object
respons
note
dog
refractori
dog
median
remiss
durat
day
given
eas
administr
equival
activ
administr
schedul
sought
gener
addit
data
regard
efficaci
regimen
complet
prospect
clinic
trial
addit
explor
potenti
concomit
prednison
mitig
previous
observ
cutan
pulmonari
advers
effect
dog
cytolog
histolog
confirm
lymphoma
treat
rabacfosadin
mgkg
free
base
iv
infus
everi
day
dog
receiv
concomit
prednison
mgkg
po
qod
throughout
treatment
dog
experienc
complet
respons
cr
receiv
dose
rabacfosadin
follow
monthli
recheck
complet
clinicopatholog
assess
clinic
assess
remiss
advers
effect
ae
perform
everi
day
respons
assess
accord
publish
vcog
criteria
ae
accord
dog
prospect
enrol
evalu
respons
assess
evalu
progress
free
interv
pfi
assess
evalu
dog
receiv
singl
line
previou
treatment
major
dog
receiv
line
previou
therapi
evalu
dog
b
cell
lymphoma
cell
lymphoma
overal
respons
rate
orr
cr
pr
orr
b
cell
cell
respect
degre
impact
respons
rate
orr
dog
dog
treat
beyond
median
pfi
day
dog
experienc
cr
day
pr
overal
median
pfi
day
degre
significantli
impact
pfi
day
line
respect
major
ae
mild
gastrointestin
gi
hematolog
ae
common
grade
ae
includ
liver
enzym
elev
lethargi
gi
urinari
dog
experienc
grade
hematolog
toxic
develop
sever
hemorrhag
gastroenter
lead
euthanasia
sever
week
first
rabacfosadin
treatment
therefor
uncertain
attribut
dog
experienc
grade
dermatolog
ae
dog
develop
grade
pulmonari
fibrosi
conclus
rabacfosadin
gener
well
toler
substanti
antitumor
activ
dog
refractori
lymphoma
administ
schedul
respons
rate
pfi
observ
studi
compar
histor
data
rabacfosadin
degre
account
reduct
frequenc
sever
ae
rel
histor
data
howev
clear
whether
result
less
frequent
dose
concurr
prednison
lower
cumul
rabacfosadin
exposur
heavili
popul
studi
warrant
explor
rabacfosadin
higher
dose
mario
dolera
luca
malfassi
massimo
sala
giovanni
mazza
simon
pavesi
silvia
marcarini
nanci
carrara
sara
finesso
la
cittadina
fondazion
studi
e
ricerch
veterinari
romanengo
itali
lower
urinari
tract
transit
cell
carcinoma
cct
pose
challeng
order
appropri
radiotherapi
rt
regimen
organ
risk
oar
within
irradi
field
uret
rectum
limit
factor
dose
escal
primari
aim
studi
evalu
technic
feasibl
dynam
imrt
lower
urinari
cct
affect
dog
secondari
goal
evalu
toxic
efficaci
rt
regimen
three
dog
lower
urinari
tract
cct
treat
definit
rt
volumetr
modul
arc
therapi
vmat
techniqu
volum
treatment
definit
includ
gross
tumor
gtv
mm
limphat
entir
bladder
prostat
male
uretra
entir
pelvi
except
rectal
volum
dose
prescript
gy
gy
gy
gy
fraction
altern
day
piroxicam
subminist
dog
serial
clinic
ctmri
examin
perform
diseas
control
toxic
effect
evalu
accord
recist
vrtog
criteria
three
urinari
tract
cct
treat
prescript
goal
obtain
three
case
mean
month
one
partial
respons
two
complet
respons
obtain
two
grade
cystiti
develop
non
rectal
toxic
recogn
initi
experi
rt
regimen
adopt
indic
feasibl
effect
lower
urinari
cct
longer
larger
treatment
seri
need
luca
malfassi
mario
dolera
simon
pavesi
massimo
sala
giovanni
mazza
silvia
marcarini
nanci
carrara
sara
finesso
la
cittadina
fondazion
studi
e
ricerch
veterinari
romanengo
itali
prognosi
canin
nasal
tumour
intracrani
extens
poor
expect
surviv
month
palliat
month
irradi
howev
studi
regard
stage
iv
nasal
tumour
treat
irradi
techniqu
lack
aim
prospect
studi
evalu
feasibl
efficaci
definit
intent
stereotact
radiotherapi
dog
nasal
tumour
massiv
intracrani
extens
seven
dog
stage
iv
nasal
tumour
treat
stereotact
radiotherapi
vmat
techniqu
dose
prescript
gy
four
fraction
gross
tumour
gy
limphat
adjuv
treatment
includ
carboplatin
serial
clinic
ctmri
examin
perform
diseas
control
toxic
effect
evalu
accord
recist
vrtog
criteria
median
surviv
time
mst
evalu
use
curv
six
carcinoma
sarcoma
treat
prescript
goal
obtain
four
case
wherea
dog
accept
limit
maximum
brain
punctual
dose
gy
two
partial
respons
complet
respons
obtain
mst
month
one
grade
ii
late
brain
radiotox
two
brain
ascend
infect
observ
relaps
pathway
involv
diffus
mening
sphenoid
invas
initi
experi
rt
regimen
adopt
indic
feasibl
effect
modifi
stage
iv
nasal
tumour
relaps
pathway
observ
suggest
evalu
altern
adjuv
treatment
dog
treat
stereotact
radiotherapi
jacki
wypij
sara
goldschmidt
holli
pondeni
univers
illinoi
urbana
illinoi
usa
forkhead
box
transcript
factor
regul
cell
cycl
progress
angiogenesi
apoptosi
increas
observ
human
lymphomaleukemia
recogn
prognost
factor
therapeut
target
thiostrepton
antibiot
use
commerci
veterinari
topic
product
put
inhibitor
purpos
studi
evalu
express
pathway
protein
canin
lymphoma
cell
line
evalu
effect
inhibitor
thiostrepton
canin
lymphoma
vitro
four
canin
lymphoma
cell
line
osw
use
western
blot
perform
assess
protein
express
pathway
protein
cyclin
b
survivin
canin
lymphoma
cell
treat
thiostrepton
hour
cell
viabil
cell
prolifer
cell
death
assess
commerci
mt
assay
trypan
blue
exclus
canin
lymphoma
cell
line
express
pathway
protein
thiostrepton
decreas
cell
viabil
manner
p
vitro
result
support
pathway
put
target
canin
lymphoma
inhibitor
thiostrepton
activ
vitro
result
warrant
evalu
thiostrepton
vitro
canin
lymphoma
research
may
lead
valid
drug
repurpos
topic
compound
treatment
canin
lymphoma
may
particularli
relev
cutan
lymphoma
jacki
wypij
univers
illinoi
urbana
illinoi
usa
limit
effect
treatment
option
avail
felin
cancer
patient
one
mechan
new
drug
develop
drug
reposit
pharmaceut
inher
activ
benzimidazol
mebendazol
mbz
put
novel
mitot
spindl
inhibitor
purpos
studi
evalu
potenti
synerg
mbz
tradit
mitot
spindl
inhibitor
vitro
evalu
mbz
effect
vitro
tubulin
polymer
evalu
serum
tubulin
polymer
activ
healthi
cat
treat
mbz
two
felin
cancer
cell
line
oral
squamou
cell
carcinoma
felin
mammari
carcinoma
incub
mbz
vinorelbin
variou
concentr
hour
cell
prolifer
assess
commerci
mt
assay
synerg
comput
util
combin
index
two
healthi
adult
cat
treat
mgkg
mbz
daili
commerci
assay
use
assess
direct
tubulin
polymer
activ
mbz
well
tubulin
polymer
treat
cat
sera
mbz
decreas
cell
prolifer
p
appear
synergist
vinorelbin
mbz
decreas
rate
total
polymer
tubulin
vitro
measur
decreas
tubulin
polymer
activ
serum
treat
cat
mbz
demonstr
vitro
effect
felin
cancer
cell
line
mbz
well
toler
vivo
result
measur
activ
treat
cat
given
known
low
toxic
mbz
may
potenti
candid
futur
clinic
trial
pet
cat
cancer
gk
dr
l
g
b
e
l
g
b
wm
care
cancer
center
california
veterinari
specialist
carlsbad
california
usa
therapeut
inc
kansa
citi
kansa
usa
manag
human
lymphoprolif
disord
includ
diffus
larg
lymphoma
dlbcl
includ
monoclon
antibodi
target
antigen
aggress
form
dlbcl
mani
similar
common
form
lymphoma
dog
addit
antibodi
rituximab
chemotherapi
treatment
dlbcl
human
associ
littl
increas
toxic
yet
enhanc
efficaci
studi
evalu
monoclon
antibodi
bind
specif
canin
antigen
canin
mab
use
chemotherapi
dog
enrol
prospect
random
blind
studi
treat
one
cycl
chemotherapi
random
either
receiv
treatment
canin
mab
placebo
remiss
lost
dog
receiv
one
dose
doxorubicin
follow
treatment
canin
mab
efficaci
assess
evalu
measur
lymph
node
cytolog
clinic
statu
safeti
base
veterinari
cooper
oncolog
group
common
terminolog
criteria
dog
n
enrol
random
measur
flow
cytometr
immunophenotyp
dlbcl
median
overal
surviv
time
canin
mab
arm
studi
day
respect
compar
day
placebo
arm
advers
event
restrict
cycl
canin
mab
conjunct
caus
signific
increas
surviv
dog
dlbcl
ami
jenna
chand
christina
susan
kristen
cheryl
william
erika
david
michael
jeffrey
kimberli
carolyn
jennif
sandra
lisa
jiup
joesph
thoma
oncolog
program
center
cancer
research
nation
cancer
institut
bethesda
maryland
usa
davi
school
veterinari
medicin
davi
california
usa
state
univers
colleg
veterinari
medicin
fort
collin
colorado
usa
bioscienc
ohio
state
univers
columbu
ohio
usa
veterinari
medicin
univers
pennsylvania
philadelphia
pennsylvania
usa
veterinari
medicin
univers
wisconsin
madison
wisconsin
usa
univers
colleg
veterinari
medicin
west
lafayett
indiana
usa
veterinari
medicin
surgeri
colleg
veterinari
medicin
univers
columbia
missouri
usa
clinic
scienc
cum
school
veterinari
medicin
tuft
univers
north
grafton
massachusett
usa
cancer
treatment
diagnosi
nation
cancer
institut
bethesda
maryland
usa
human
toxicolog
pharmacolog
applieddevelopment
research
support
director
inc
frederick
nation
laboratori
cancer
research
frederick
maryland
usa
indenoisoquinolon
act
topoisomeras
inhibitor
known
activ
anticanc
agent
human
dog
clinic
trial
dog
lymphoma
conduct
nci
compar
oncolog
trial
consortium
defin
safeti
pharmacokinet
pk
pharmacodynam
modul
three
relat
novel
indenoisoquinolon
dog
lymphoma
enrol
dose
escal
phase
dog
random
receiv
consecut
intraven
daili
dose
one
agent
agent
escal
independ
dogscohort
serial
tumor
biopsi
tumor
aspir
bone
marrow
aspir
collect
two
pk
curv
complet
first
last
dose
drug
tumor
plasma
pk
level
induct
data
collect
along
clinic
toxic
respons
data
maximum
toler
dose
mtd
defin
two
three
indenoisoquinolin
mtd
reach
toxic
profil
agent
includ
expect
gastrointestin
hematolog
constitut
event
object
respons
seen
across
agent
relationship
evid
overal
respons
rate
evalu
dog
respect
correl
relationship
clinic
respons
pharmacokinet
profil
pharmacodynam
marker
establish
agent
novel
agent
studi
herein
toler
effect
dog
studi
dog
lymphoma
measur
soft
tissu
sarcoma
ongo
nicola
josephin
ana
lilian
kim
cara
falon
juli
anu
yvonn
pennsylvania
philadelphia
pennsylvania
usa
inc
princeton
new
jersey
usa
radiat
therapi
rt
induc
immunogen
tumor
cell
death
promot
immun
result
regress
metastat
lesion
phenomenon
known
abscop
effect
hypothes
combin
rt
recombin
express
immunotherapi
could
promot
immun
delay
primari
tumor
progress
prevent
metastat
diseas
dog
osteosarcoma
ten
dog
histopatholog
confirm
treatment
appendicular
osteosarcoma
enrol
pilot
studi
dog
receiv
gy
rt
fraction
consecut
day
follow
intraven
everi
week
administr
radiograph
perform
week
everi
month
thereaft
assess
primari
tumor
progress
develop
pulmonari
metastas
time
dog
evalu
toxic
lame
qualiti
life
qol
pbmc
collect
evalu
specif
cell
respons
primari
endpoint
time
progress
ttp
secondari
end
point
safeti
overal
surviv
repeat
administr
well
toler
lame
qol
improv
dog
present
dog
still
aliv
dose
dog
show
minim
radiograph
evid
primari
tumor
progress
dog
develop
pulmonari
metastat
diseas
suffer
patholog
fractur
median
ttp
day
median
surviv
time
day
immunolog
assess
pend
result
compar
favor
histor
report
rt
alon
warrant
perform
random
placebo
control
clinic
trial
frank
cailin
lisa
joel
lisa
school
veterinari
medicin
north
grafton
massachusett
usa
human
nutrit
research
center
tuft
univers
boston
massachusett
usa
human
obes
exacerb
mani
type
cancer
increas
risk
cancer
develop
tumor
aggress
recurr
risk
cancer
death
howev
relationship
dog
thoroughli
evalu
aim
studi
determin
whether
bodi
condit
score
bc
time
lymphoma
lsa
osteosarcoma
osa
diagnosi
dog
predict
surviv
time
st
hypothes
overweight
bc
time
cancer
diagnosi
would
associ
shorter
st
medic
record
dog
diagnos
treat
lsa
osa
review
data
signal
bodi
weight
bc
treatment
surviv
collect
dog
group
bc
underweight
normal
overweight
st
compar
use
surviv
analysi
total
dog
lsa
osa
includ
studi
overal
dog
underweight
normal
weight
overweight
univari
analysi
st
significantli
shorter
underweight
dog
lsa
p
osa
p
dog
lsa
gain
bodi
weight
diagnosi
longer
st
p
multivari
analysi
dog
chang
bodi
weight
p
anemia
p
bc
group
significantli
associ
st
conclus
although
relationship
bc
st
detect
chang
bodi
weight
diagnosi
associ
st
patrick
kenni
christoph
scudder
sophi
keyt
jame
swann
robert
fowk
david
church
yaiza
forcada
stijn
niessen
royal
veterinari
colleg
london
uk
hypersomatotrop
hs
import
caus
diabet
mellitu
dm
cat
though
excis
somatotrophinoma
gener
recommend
human
hs
surgic
therapi
far
infrequ
report
cat
aim
describ
efficaci
hypophysectomi
treatment
hs
morbid
mortal
encount
cohort
cat
hypophysectomi
offer
owner
present
diabet
cat
confirm
hs
growth
ngml
pituitari
mass
royal
veterinari
colleg
sinc
cat
oper
one
neurosurgeon
hypophysectomi
perform
manual
extirp
use
fine
surgic
tool
via
approach
cat
rigidli
posit
commerci
avail
surgic
head
frame
approach
pituitari
fossa
guid
referenc
boni
landmark
comput
tomograph
scan
cat
receiv
intens
monitor
electrolyt
glucos
blood
pressur
initi
administ
conjunctiv
desmopressin
ddavp
intraven
infus
insulin
hydrocortison
transit
conjunctiv
ddavp
oral
hydrocortison
levothyroxin
subcutan
glargin
insulin
total
diabet
cat
hs
underw
hypophysectomi
april
oct
median
rang
age
year
pituitari
height
mm
ngml
fructosamin
mild
pelvic
limb
weak
cat
display
overt
neurolog
deficit
prior
surgeri
three
cat
die
two
cat
recov
anaesthesia
euthan
within
hour
one
cat
develop
septic
mening
euthan
day
surviv
cat
n
saw
reduct
serum
cat
show
normal
median
serum
ngml
wilcoxon
sign
rank
test
p
fourteen
surviv
cat
achiev
diabet
remiss
remain
achiev
superior
glycaem
control
lower
insulin
dosag
median
fructosamin
respect
median
insulin
dose
unitskgday
respect
congest
heart
failur
encount
transient
problem
cat
recov
surgeri
case
occur
prior
implement
reduct
volum
intraven
fluid
deliv
part
protocol
two
cat
develop
paresi
left
orbiculari
oculi
muscl
resolv
surviv
cat
cardiac
arrest
occur
cat
time
jugular
cathet
placement
success
reviv
made
unev
recoveri
one
cat
develop
left
pelvic
limb
monoparesi
improv
resolv
palat
wound
breakdown
encount
hypophysectomi
treatment
felin
hsdm
result
high
incid
diabet
remiss
resolut
hs
chen
gilor
rebecca
glock
shir
gilor
ohio
state
univers
columbu
ohio
usa
role
glucagon
disturb
diabet
increasingli
recogn
glucagon
stimul
test
describ
healthi
diabet
cat
previous
inform
lack
respons
healthi
cat
glucagon
specif
condit
aim
studi
assess
effect
diurnal
variat
durat
fast
respons
glucagon
healthi
cat
five
healthi
cat
use
studi
cat
regularli
hour
minut
glucagon
stimul
test
im
perform
cat
time
week
apart
hour
hour
fast
hour
hour
fast
hour
hour
fast
glucos
insulin
concentr
measur
minut
post
stimul
baselin
mean
zero
minut
peak
concentr
compar
use
friedman
test
p
consid
signific
baselin
glucos
insulin
differ
significantli
treatment
group
peak
glucos
concentr
occur
minut
significantli
higher
p
mean
sd
mgdl
differ
mgdl
mgdl
similarli
peak
insulin
concentr
occur
minut
significantli
higher
p
ngl
differ
ngl
ngl
conclus
prolong
fast
hour
significantli
blunt
glycem
respons
glucagon
compar
shorter
fast
hour
diurnal
variat
signific
effect
glucos
insulin
respons
david
patrick
elena
duncan
alexand
biopharma
melbourn
victoria
australia
carolina
state
univers
raleigh
north
california
usa
option
manag
chronic
pain
cat
extrem
limit
particular
use
nsaid
limit
potenti
signific
side
effect
safe
effect
analges
cat
highli
desir
neutral
monoclon
antibodi
mab
nerv
growth
factor
ngf
analges
rodent
model
human
osteoarthr
use
novel
techniqu
convers
antibodi
base
express
cdna
sequenc
analysi
petiz
recent
describ
mab
allevi
pain
due
osteoarthr
dog
use
approach
describ
design
develop
novel
therapeut
mab
allevi
pain
cat
petiz
amino
acid
sequenc
mab
heavi
light
chain
convert
cdna
sequenc
complet
chemic
synthesi
clone
mammalian
cell
express
vector
express
chines
hamster
ovari
cho
cell
free
media
mab
purifi
homogen
affin
chromatographi
steril
filtrat
purifi
mab
demonstr
high
affin
potenc
neutral
ngf
bind
complement
pilot
studi
advers
event
observ
follow
inject
mab
iv
sc
four
cat
mab
elimin
approxim
week
induc
neutral
antibodi
follow
repeat
inject
studi
use
kaolin
model
inflammatori
pain
cat
demonstr
mab
effect
reduc
sign
lame
due
inflamm
manner
p
togeth
data
suggest
mab
potenti
safe
effect
therapeut
analges
cat
studi
progress
cat
degen
joint
diseas
christian
nanci
jane
peter
laboratori
inc
west
sacramento
california
usa
univers
utrecht
netherland
felin
coronavirus
fcov
occur
pathotyp
enigmat
even
controversi
relationship
low
virul
nonvirul
felin
enter
coronaviru
fecv
highli
lethal
felin
infecti
periton
viru
fipv
recent
describ
spike
gene
mutat
within
put
fusion
region
describ
correl
mutat
form
fcov
fipv
lead
clinic
present
felin
infecti
periton
fip
present
develop
valid
allel
discrimin
pcr
type
test
identifi
mutat
separ
describ
diagnost
sensit
specif
report
set
european
clinic
sampl
acquir
either
fip
confirm
cat
healthi
cat
previous
test
fcov
posit
archiv
sampl
fcov
posit
sampl
includ
valid
sampl
pass
qualiti
control
viru
level
limit
detect
pcr
assay
remain
sampl
type
correctli
accuraci
one
fip
character
sampl
type
fecv
diagnost
sensit
healthi
cat
type
fecv
diagnost
specif
confirm
spike
gene
mutat
uniqu
european
cat
fip
addit
valid
studi
us
japanes
sampl
conduct
us
clinic
studi
includ
case
fip
suspici
case
compat
diseas
fipv
realpcr
biotyp
assay
abl
accur
differenti
fip
fecv
etiolog
p
biotyp
cat
confirm
diseas
fipv
confirm
high
diagnost
specif
molecular
test
lisa
sean
linda
bill
cum
school
veterinari
medicin
north
grafton
massachusett
usa
therapeut
inc
pari
franc
consult
dublin
ireland
therapeut
inc
kansa
citi
kansa
usa
thin
bodi
condit
weight
loss
muscl
loss
common
cat
chronic
kidney
diseas
ckd
howev
time
cours
progress
weight
loss
diagnosi
thoroughli
evalu
therefor
purpos
retrospect
analysi
describ
weight
loss
experienc
cat
ckd
diagnosi
cat
ckd
us
veterinari
practic
intern
renal
interest
group
iri
stage
avail
elig
age
date
ckd
diagnosi
weight
measur
avail
year
diagnosi
includ
analysi
total
cat
mean
age
diagnosi
year
evalu
spay
femal
castrat
male
cat
categor
diagnosi
iri
stage
n
stage
n
stage
n
stage
n
median
bodi
weight
diagnosi
kg
rang
kg
cat
lost
median
bodi
weight
month
diagnosi
weight
loss
began
earli
year
diagnosi
acceler
diagnosi
ckd
cat
median
bodi
weight
kg
diagnosi
significantli
shorter
surviv
time
compar
cat
kg
diagnosi
p
weight
loss
detect
cat
diagnosi
ckd
acceler
diagnosi
associ
surviv
care
monitor
could
benefit
felin
health
eva
valeri
jordan
susan
john
minnesota
colleg
veterinari
medicin
saint
paul
minnesota
usa
ohio
state
univers
colleg
veterinari
medicin
columbu
ohio
usa
washington
school
medicin
seattl
washington
usa
veterinari
specialist
charlott
north
california
usa
laboratori
rodent
spontan
hyperlipidemia
develop
glomerular
injuri
proteinuria
idiopath
hypertriglyceridemia
common
miniatur
schnauzer
previou
report
demonstr
possibl
link
proteinuria
breed
object
studi
evalu
relationship
hypertriglyceridemia
proteinuria
miniatur
schnauzer
miniatur
schnauzer
dog
enrol
studi
fast
serum
triglycerid
urin
ratio
upc
determin
relationship
two
variabl
analyz
test
simpl
linear
regress
well
multipl
regress
includ
age
sex
bodi
condit
score
covari
nine
dog
normal
serum
triglycerid
concentr
median
mgdl
rang
mgdl
dog
hypertriglyceridemia
median
mgdl
rang
mgdl
strong
posit
correl
triglycerid
concentr
upc
r
p
ten
dog
hypertriglyceridemia
proteinuria
upc
compar
none
dog
normal
triglycerid
concentr
p
proteinuria
sever
dog
triglycerid
concentr
mgdl
dog
triglycerid
concentr
level
upc
none
dog
azotem
hypoalbuminem
endocrin
diseas
diagnos
dog
conclus
signific
proteinuria
present
dog
idiopath
hypertriglyceridemia
may
due
glomerular
injuri
longitudin
studi
evalu
renal
patholog
warrant
investig
find
stephani
smith
maureen
mcmichael
ron
achiel
katrina
jung
univers
illinoi
urbana
illinoi
usa
recent
discov
stimul
neutrophil
releas
chromatin
fiber
decor
enzym
form
extracellular
trap
net
format
net
netosi
associ
histon
hypercitrullin
net
part
innat
immun
respons
also
associ
thrombosi
organ
damag
autoimmun
prospect
observ
studi
edta
plasma
collect
appar
healthi
dog
dog
imha
plasma
dna
concentr
measur
dilut
sampl
fold
albumin
ad
mm
sytoxgreen
fluoresc
record
correct
autofluoresc
use
dilut
sampl
without
sytoxgreen
dna
concentr
calcul
base
standard
curv
nucleosom
complex
quantifi
elisa
normal
canin
pool
normal
plasma
defin
presenc
citrullin
histon
plasma
confirm
use
western
blot
result
compar
healthi
imha
dog
wilcoxon
rank
sum
test
plasma
dog
imha
median
rang
contain
significantli
p
higher
concentr
free
dna
normal
plasma
median
rang
imha
plasma
also
contain
significantli
p
higher
concentr
nucleosom
median
rang
compar
normal
plasma
median
rang
plasma
dog
imha
contain
citrullin
histon
marker
identifi
healthi
dog
excess
netosi
appear
featur
canin
imha
may
contribut
prothrombot
state
diseas
kati
tolbert
emili
gould
mabr
brand
univers
tennesse
knoxvil
tennesse
usa
tritrichomona
foetu
tf
mucos
protozoan
parasit
infect
felin
distal
ileum
proxim
colon
result
chronic
diarrhea
tf
worldwid
distribut
consist
effect
drug
treat
infect
cystein
proteas
cp
recent
demonstr
promot
cytotox
felin
tf
intestin
epithelium
result
support
investig
cp
inhibitor
potenti
therapeut
target
amelior
patholog
effect
felin
trichomonosi
reduc
host
toxic
drug
must
tailor
inhibit
proteas
produc
pathogen
respons
cytopath
effect
redund
mechan
product
function
host
proteas
thu
aim
studi
investig
current
avail
cp
inhibitor
feasibl
target
specif
region
felin
tf
cp
activ
amelior
cytopathogen
effect
small
molecul
cp
inhibitor
specif
cp
activ
protein
extract
obtain
felin
tf
isol
identifi
mean
gel
zymographi
presenc
absenc
mm
calpain
inhibitor
antipain
cystatin
leupeptin
chymostatin
wrr
effect
inhibit
specif
cp
activ
tf
cytopathogen
determin
use
felin
tf
allow
adher
monolay
porcin
intestin
epitheli
cell
cytopathogen
effect
tf
follow
inhibit
specif
cp
activ
evalu
light
microscopi
crystal
violet
spectrophotometr
analysi
immunoblot
cell
antigen
cleav
cytokeratin
marker
apoptosi
minimum
replic
perform
cytotox
experi
data
analyz
use
systat
softwar
p
pattern
gel
zymographi
demonstr
differ
felin
isol
tf
similar
reveal
abil
vinyl
sulfon
cp
inhibitor
wrr
cystatin
target
specif
zone
felin
tf
cp
activ
inhibitor
effect
tf
growth
significantli
inhibit
cytotox
toward
intestin
epithelium
felin
tf
isol
test
p
studi
establish
current
avail
inhibitor
cystein
proteas
capabl
inhibit
specif
region
felin
tf
cystein
proteas
activ
amelior
cytopathogen
intestin
epithelium
vitro
result
studi
provid
strong
justif
identif
specif
cystein
proteas
inhibit
moreov
examin
effect
specif
cystein
proteas
inhibitor
amelior
clinic
sign
cat
natur
infect
tf
warrant
philippa
allyson
chick
demetriu
anim
medic
center
new
york
new
york
usa
jefferson
univers
philadelphia
pennsylvania
usa
ureter
obstruct
seriou
clinic
problem
dog
tradit
surgeri
associ
high
complic
rate
ureter
stent
provid
option
immedi
decompress
consid
human
medicin
describ
use
ureter
stent
dog
benign
ureter
obstruct
hypothes
safe
effect
treatment
option
diagnosi
benign
ureter
obstruct
made
via
ultrasonographi
radiographi
ureteropyelographi
ureter
stent
place
endoscop
andor
surgic
medic
record
review
intra
postop
data
outcom
dog
uret
underw
stent
placement
ureterolithiasi
strictur
endoscopicfluoroscop
surgicalfluoroscop
techniqu
success
uret
respect
azotemia
present
median
mgdl
remain
azotem
median
decompress
urinari
tract
infect
present
clear
treatment
periop
mortal
rate
three
major
complic
occur
stent
placement
major
complic
requir
intervent
occur
respect
median
time
day
rang
aliv
last
find
suggest
ureter
stent
safe
effect
minim
invas
short
treatment
option
benign
ureter
obstruct
dog
complic
typic
minor
may
necessit
stent
exchang
use
altern
devic
mahalakshmi
murthi
edward
denni
jean
laboratori
inc
westbrook
main
usa
pet
nutrit
inc
topeka
kansa
usa
state
univers
corval
oregon
usa
sdma
one
dimethyl
deriv
arginin
releas
cytoplasm
proteolysi
circul
sdma
mostli
elimin
kidney
plasma
concentr
affect
chang
gfr
previous
shown
increas
serum
sdma
concentr
observ
cat
dog
reduc
renal
function
also
demonstr
serum
sdma
allow
earlier
detect
chronic
kidney
diseas
ckd
cat
dog
compar
serum
creatinin
gener
serum
sdma
creatinin
concentr
correl
howev
ckd
patient
sdma
concentr
increas
disproportion
compar
serum
creatinin
discord
seen
cat
dog
preval
much
higher
cat
observ
discord
ckd
patient
quantifi
term
sdma
creatinin
ratio
higher
ratio
greater
discord
although
typic
sdma
creatinin
ratio
major
anim
ckd
observ
larger
sdma
creatinin
ratio
ckd
patient
greater
chanc
mortal
note
ratio
appli
ckd
anim
dog
cat
creatinin
andor
sdma
concentr
within
normal
limit
ratio
previous
report
upper
normal
refer
limit
sdma
dog
cat
exampl
retrospect
studi
consist
ckd
cat
sdma
creatinin
ratio
deceas
within
year
wherea
ckd
cat
normal
ratio
sdma
creatinin
still
aliv
time
similar
trend
observ
anoth
studi
dog
surviv
curv
gener
cat
dog
base
sdma
concentr
greater
less
cat
sdma
surviv
approxim
time
longer
cat
sdma
dog
sdma
surviv
approxim
time
longer
compar
dog
sdma
cat
dog
maintain
high
qualiti
care
includ
optim
nutrit
veterinari
health
care
opportun
social
play
time
caretak
daili
opportun
exercis
play
toy
elev
sdma
concentr
gener
sdma
creatinin
ratio
particular
felin
canin
ckd
patient
could
potenti
provid
prognost
valu
result
warrant
studi
jonathan
fogl
yan
wang
north
carolina
state
univers
colleg
veterinari
medicin
raleigh
north
california
usa
gener
matur
lymphocyt
depend
upon
epigenet
chang
dna
demethyl
histon
acetyl
promot
region
cytokin
essenti
cell
function
differenti
convers
dysfunct
cell
exhibit
alter
pattern
methyl
acetyl
failur
complet
differenti
suggest
earli
transcript
event
contribut
induct
cell
dysfunct
mani
persist
viral
infect
herp
simplex
viru
hsv
hepat
c
viru
hcv
rotaviru
rv
human
immunodefici
viru
hiv
felin
immunodefici
viru
fiv
viru
specif
cell
activ
follow
induct
cell
dysfunct
character
lack
product
poor
prolifer
follow
cell
receptor
tcr
stimul
loss
product
signal
onset
progress
declin
cytokin
product
antivir
function
use
felin
immunodefici
model
fiv
lentivir
persist
clearli
demonstr
regulatori
treg
cell
provid
strong
inhibitori
signal
induc
cell
cycl
arrest
activ
lymphocyt
target
earli
progress
cours
infect
shown
treg
cell
activ
fiv
infect
induc
express
repress
transcript
factor
cell
target
follow
treg
cell
cocultur
final
recent
demonstr
bind
promot
bulk
viru
cell
block
epigenet
rearrang
prevent
bind
promot
viru
cell
recent
find
laboratori
suggest
earli
epigenet
chang
histon
acetyl
dna
demethyl
essenti
antivir
function
render
cell
highli
permiss
repress
transcript
hypothesi
activ
treg
cell
exploit
epigenet
chang
cell
caus
dysfunct
purpos
investig
demonstr
bind
promot
viru
specif
cell
use
chromatin
immunoprecipit
chip
bisulfit
reduct
dna
assess
histon
acetyl
dna
demethyl
promot
region
viru
specif
cell
fiv
cat
briefli
viru
specif
cell
identifi
prolifer
respons
inactiv
viru
cell
purifi
autolog
treg
cell
concert
previou
work
viru
cell
data
suggest
follow
cocultur
autolog
treg
cell
viru
specif
cell
exhibit
increas
mrna
decreas
mrna
n
importantli
recent
chip
studi
demonstr
bind
promot
viru
specif
cell
fiv
cat
follow
treg
cell
cocultur
n
collect
result
suggest
possibl
block
epigenet
rearrang
viru
specif
cell
therebi
block
bind
promot
mechanist
studi
provid
new
avenu
investig
restor
antivir
cell
function
cours
persist
viral
infect
polina
georg
mark
jane
davi
vmth
davi
california
usa
davi
school
medicin
davi
california
usa
carolina
unvers
raleigh
north
california
usa
voriconazol
potent
azol
antifung
drug
contraind
cat
advers
effect
sought
determin
pharmacokinet
voriconazol
healthi
cat
oral
iv
administr
safe
dose
might
establish
six
cat
administ
mgkg
voriconazol
iv
plasma
voriconazol
concentr
measur
multipl
time
point
hour
administr
use
high
perform
liquid
chromatographi
subsequ
voriconazol
suspens
administ
group
cat
mgkg
po
plasma
concentr
measur
multipl
time
point
hour
administr
pharmacokinet
tablet
suspens
prepar
also
compar
use
rang
dose
mgkg
plasma
measur
perform
period
administr
voriconazol
iv
administr
approxim
hour
oral
administr
maxim
plasma
concentr
reach
minut
dose
mgkg
result
optim
plasma
drug
concentr
predict
oral
administr
hour
advers
effect
includ
hypersaliv
coincid
oral
suspens
administr
tablet
miosi
miosi
associ
peak
plasma
voriconazol
level
persist
hour
voriconazol
excel
oral
bioavail
cat
oral
dose
mgkg
may
maintain
adequ
antifung
plasma
concentr
administr
studi
requir
miosi
signific
advers
effect
occur
plasma
concentr
high
end
target
rang
recommend
human
roschel
michael
page
jill
michigan
univers
mt
pleasant
michigan
usa
point
veterinari
hospit
canton
michigan
usa
object
studi
describ
knowledg
attitud
belief
kab
nation
sampl
owner
regard
end
life
eol
care
pet
hypothesi
includ
paradigm
eol
depend
factor
owner
educ
eol
decis
influenc
mani
variabl
requir
larg
sampl
n
data
segment
addit
object
includ
describ
eol
qualiti
life
qol
awar
belief
regard
pain
manag
pm
recognit
term
home
care
pet
owner
studi
exempt
categori
anonym
survey
feder
statut
institut
review
board
computer
link
open
inform
consent
instrument
develop
modif
valid
survey
kab
eol
veterinarian
specialti
associ
known
involv
eol
qol
consult
follow
owner
focu
group
pilot
design
survey
data
password
protect
recruit
social
media
perform
data
process
spss
respond
age
year
petshousehold
pet
age
year
pet
losseslifetim
first
time
pet
owner
pet
health
insur
respond
primarili
femal
caucasian
marri
religi
unaffili
educ
hs
occup
familiar
hospic
home
eol
care
pet
qol
rate
scale
willing
use
qol
scale
futur
term
pm
eol
care
owner
like
like
use
oral
medic
pill
form
liquid
inject
acupunctur
acupressuremassag
physic
therapi
hydrotherapi
surgeri
nerv
block
corticosteroid
inject
opt
euthanasia
includ
chiropract
transderm
patch
laser
herbal
naturopathi
aromatherapi
prayer
etc
percent
owner
report
fiscal
concern
influenti
continu
eol
care
pain
could
control
almost
owner
said
would
euthan
data
segment
warrant
discern
differ
among
owner
regard
kab
eol
pm
qol
euthanasia
find
provid
basi
educ
outreach
protocol
develop
owner
ill
geriatr
anim
hiroshi
research
group
inc
tokyo
japan
inc
tokyo
japan
overcom
alopecia
relat
varieti
diseas
pet
identifi
materi
promot
hair
growth
particularli
bald
spot
lead
develop
product
help
field
food
medicin
develop
composit
promot
hair
growth
anim
use
numer
formul
includ
drug
dress
adhes
bandag
supplement
food
snack
water
hair
care
suppli
dental
suppli
cloth
shoe
sock
formul
contain
lipopolysaccharid
lp
activ
ingredi
lp
tablet
pine
bark
polyphenol
tablet
oral
administ
dog
cat
rabbit
hamster
alopecia
studi
conduct
japan
cooper
practition
studi
involv
restrict
food
intak
medic
prohibit
concomit
use
supplement
anim
divid
group
receiv
lp
tablet
alon
receiv
lp
tablet
pine
bark
polyphenol
tablet
durat
studi
approxim
day
hair
growth
note
anim
administ
lp
tablet
alon
anim
administ
lp
tablet
pine
bark
polyphenol
tablet
jill
ami
nyssa
edward
j
anim
health
madison
new
jersey
usa
york
state
veterinari
diagnost
laboratori
cornel
univers
ithaca
new
york
usa
canin
infecti
respiratori
diseas
complex
cirdc
common
diseas
complex
caus
mani
differ
virus
bacteria
includ
bordetella
bronchiseptica
mycoplasma
cyno
adenoviru
type
distemp
influenza
viru
parainfluenza
viru
pneumoviru
respiratori
coronaviru
march
veterinarian
chicago
area
note
increas
incid
sign
canin
infecti
respiratori
diseas
dog
nasal
pharyng
swab
dog
show
clinic
sign
submit
cornel
univers
anim
health
diagnost
center
ahdc
canin
respiratori
polymeras
chain
reaction
pcr
screen
panel
util
allow
identif
follow
cirdc
pathogen
b
bronchiseptica
mycoplasma
cyno
adenoviru
type
distemp
influenza
parainfluenza
viru
pneumoviru
respiratori
coronaviru
march
diagnost
sampl
program
initi
test
sampl
dog
respiratori
sign
use
screen
panel
april
sampl
collect
report
clinic
ship
base
cornel
ahdc
specif
screen
sick
dog
dog
test
posit
canin
influenza
use
pcr
assay
none
test
dog
confirm
influenza
strain
test
cornel
univers
wisconsin
identifi
strain
canin
influenza
influenza
viru
avian
origin
first
isol
clinic
ill
dog
china
south
korea
canin
influenza
viru
associ
sever
respiratori
sign
clinic
sign
fever
reduc
bodi
weight
interstiti
pneumonia
addit
dog
test
posit
parainfluenza
viru
nine
dog
test
posit
b
bronchiseptica
three
dog
test
posit
adenoviru
type
dog
test
posit
pneumoviru
dog
test
posit
respiratori
coronaviru
record
review
determin
vaccin
statu
posit
dog
none
dog
test
posit
influenza
viru
vaccin
influenza
viru
dog
test
posit
parainfluenza
viru
receiv
inject
distemp
adenoviru
type
parvoviru
parainfluenza
viru
combin
vaccin
receiv
monoval
b
bronchiseptica
vaccin
five
vaccin
intranas
b
bronchiseptica
parainfluenza
combin
product
five
dog
receiv
b
bronchiseptica
combin
vaccin
time
vaccin
suggest
viru
sampl
may
vaccin
origin
inform
gather
test
program
repres
first
time
influenza
viru
isol
dog
unit
state
point
origin
could
determin
addit
data
collect
support
role
parainfluenza
viru
major
prevent
pathogen
cirdc
rout
vaccin
consid
vaccin
protocol
daniela
bedenic
samuel
jen
mauricio
solano
mari
rose
paradi
cum
school
veterinari
medicin
tuft
univers
north
grafton
massachusett
usa
studi
purpos
evalu
clinic
characterist
neonat
foal
fulfil
criteria
neonat
ali
nali
ard
nard
retrospect
cohort
analysi
foal
admit
univers
hospit
old
perform
diagnost
criteria
nali
nard
appli
preexist
databas
includ
patient
later
thorac
radiograph
arteri
blood
ga
result
obtain
room
air
within
neonat
born
follow
induct
diagnosi
prematur
exclud
diagnost
threshold
adjust
age
previous
describ
thorac
radiograph
evalu
use
score
system
histopatholog
abnorm
grade
accord
distribut
frequenc
edemacongestionhypercellular
fibrin
exud
hyalin
membran
pneumocyt
hyperplasia
interstiti
fibrosi
establish
diagnosi
diffus
alveolar
damag
dad
data
present
descript
admit
foal
fulfil
clinic
threshold
criteria
nali
nard
surviv
respect
histopatholog
review
lung
tissu
avail
affect
foal
show
sever
diffus
edema
congest
patient
hyalin
membran
thu
dad
observ
rare
interstiti
fibrosi
identifi
associ
pulmonari
diagnos
foal
dad
includ
meconium
aspir
n
infect
n
suppur
bronchopneumonia
n
conclus
histopatholog
show
exud
rather
prolif
fibrot
dad
foal
nali
nard
erica
lauren
mark
stephani
state
univers
corval
oregon
usa
state
univers
stillwat
oklahoma
usa
minnesota
saint
paul
minnesota
usa
least
arabian
endur
hors
suffer
exert
rhabdomyolysi
er
unknown
etiolog
studi
compar
muscl
histopatholog
metabol
respons
field
exercis
test
endur
arabian
without
previou
er
er
n
age
year
control
n
year
hors
possess
mutat
hour
stall
rest
pair
er
control
hors
fit
telemetr
ecg
perform
minut
standard
interv
walk
trot
one
interv
canter
blood
sampl
obtain
immedi
hour
plasma
frozen
immedi
liquid
nitrogen
percutan
gluteu
mediu
muscl
sampl
frozen
liquid
nitrogen
obtain
hour
glycogen
analysi
muscl
sampl
also
fix
formalin
histopatholog
analysi
fisher
exact
test
anova
perform
p
hors
display
clinic
sign
er
serum
creatin
kinas
activ
hour
significantli
differ
er
control
arabian
muscl
glycogen
heart
rate
pcv
plasma
total
protein
glucos
lactat
electrolyt
concentr
differ
exercis
er
control
hors
er
hors
central
nuclei
matur
myofib
higher
myopath
score
compar
control
hors
arabian
endur
hors
histori
er
similar
metabol
respons
submaxim
exercis
test
healthi
arabian
spite
histopatholog
indic
chronic
er
thu
arabian
er
appear
associ
consist
metabol
myopathi
angelika
henri
miranda
mohammad
luca
scott
zurich
vetsuiss
faculti
clinic
equin
intern
medicin
zurich
switzerland
guelph
ontario
veterinari
colleg
depart
clinic
studi
guelph
ontario
canada
guelph
ontario
veterinari
colleg
depart
pathobiolog
guelph
ontario
canada
copenhagen
faculti
health
medic
scienc
depart
veterinari
diseas
biolog
frederiksberg
copenhagen
denmark
suggest
probiot
modifi
intestin
microbiota
scientif
proof
lack
object
studi
evalu
effect
probiot
contain
strain
select
activ
intestin
microbiota
neonat
foal
healthi
foal
randomli
alloc
receiv
probiot
placebo
formul
week
probiot
formul
contain
two
lactobacillu
rhamnosu
strain
two
l
plantarum
strain
b
animali
lacti
fecal
sampl
collect
week
age
mothur
analysi
next
gener
sequenc
data
use
compar
data
treatment
group
effect
treatment
group
alpha
divers
indic
chao
rich
simpson
divers
shannon
even
p
signific
differ
rel
abund
phyla
class
predomin
genera
includ
bifidobacterium
p
week
age
lactobacillu
p
week
age
sever
differ
treatemnt
group
note
use
lefs
notabl
week
unclassifi
lactobacillacea
lda
score
p
enrich
probiot
group
signific
differ
beta
divers
group
assess
unifrac
appli
jaccard
yue
clayton
tree
p
probiot
treatment
limit
effect
composit
microbiom
studi
includ
larger
number
foal
perform
assess
whether
differ
signific
use
therapeut
modifi
microbiom
foal
raffaella
teixeira
jame
mickelson
stephani
valberg
molli
mccue
univers
minnesota
st
paul
minnesota
usa
type
polysaccharid
storag
myopathi
inherit
neuromuscular
disord
caus
gain
function
skelet
muscl
glycogen
synthas
lead
excess
glycogen
abnorm
polysaccharid
accumul
muscl
fiber
hors
util
glycogen
develop
exercis
intoler
rhabdomyolysi
exercis
link
excess
glycogen
abnorm
polysaccharid
rhabdomyolysi
unknown
control
regular
exercis
low
starchhigh
fat
diet
improv
sign
hypothes
excess
glycogen
andor
improp
regul
glycogen
synthas
result
alter
gene
express
skelet
muscl
energi
metabol
pathway
lead
rhabdomyolysi
clinic
improv
daili
exercis
due
normal
gene
express
hors
gluteal
muscl
biopsi
collect
case
control
high
starch
diet
prior
train
immedi
exercis
follow
standard
train
protocol
rna
isol
sequenc
readssampl
read
map
de
novo
assembl
perform
identifi
novel
transcript
differenti
gene
express
measur
gene
differenti
express
case
control
respect
largest
differ
express
case
gene
gene
gene
involv
glycogen
metabol
glycolysi
mitochondri
electron
transport
differenti
express
case
control
understand
alter
energi
regul
lead
new
therapi
new
insight
metabol
myopathi
muscl
glycogen
regul
carri
krista
larami
aaron
jami
danika
birgit
california
davi
davi
california
usa
minnesota
st
paul
minnesota
usa
perform
equin
martnez
california
usa
equin
neuroaxon
dystrophyequin
degen
myeloencephalopathi
nadedm
neurodegen
disord
affect
genet
predispos
foal
maintain
defici
diet
first
year
life
hypothes
administr
age
would
signific
effect
serum
cerebrospin
fluid
csf
healthi
foal
serum
csf
se
would
significantli
decreas
foal
first
year
life
fourteen
quarter
hors
foal
includ
studi
ten
healthi
foal
supplement
mlkg
n
salin
n
day
age
four
unsuppl
foal
complet
neurolog
examin
blood
csf
collect
perform
day
age
supplement
day
age
day
nadedm
affect
foal
one
unsuppl
healthi
foal
euthan
full
necropsi
perform
signific
decreas
blood
csf
se
found
first
year
life
foal
signific
chang
serum
occur
day
dam
se
significantli
impact
foal
concentr
day
age
inject
significantli
increas
csf
se
blood
csf
healthi
foal
foal
significantli
lower
csf
despit
foal
remain
defici
four
genet
predispos
foal
develop
nadedm
codi
nichola
david
stephen
brett
hilari
kate
elizabeth
specialti
center
tucson
tucson
arizona
usa
state
univers
colleg
veterinari
medicin
ame
iowa
usa
current
diagnost
strategi
equin
cervic
vertebr
stenot
myelopathi
cvsm
limit
identif
structur
chang
within
vertebr
canal
infer
spinal
cord
dysfunct
delay
latenc
transcrani
magnet
motor
evok
potenti
tmmep
associ
spinal
cord
dysfunct
hors
although
histopatholog
confirm
correl
axon
loss
lack
purpos
studi
investig
relationship
tmmep
latenc
axon
loss
hors
diagnos
cvsm
hypothesi
cervic
spinal
cord
axon
loss
correl
tmmep
latenc
tmmep
latenc
hors
record
bilater
extensor
carpi
radiali
craniali
tibiali
muscl
ten
hors
clinic
sign
consist
cvsm
cvsm
group
ten
remain
hors
present
disord
control
group
hors
later
cervic
radiograph
perform
prior
human
euthanasia
cerebrospin
fluid
hors
test
neg
sarcocysti
neurona
elisa
postmortem
harvest
cervic
spinal
cord
hors
via
dorsal
laminectomi
formalin
fixat
transvers
section
cranial
dorsal
caudal
intervertebr
disc
space
tissu
block
stain
luxol
fast
blue
h
e
counterstain
digit
imag
spinal
cord
transvers
section
acquir
pixel
densiti
count
determin
adob
determin
axon
densiti
follow
locat
within
section
dorsal
later
funiculu
dlf
dorsal
funiculu
df
ventral
funiculu
vf
later
funiculu
lf
tmmep
latenc
extensor
carpi
radiali
craniali
tibiali
compar
control
affect
hors
unpair
test
ratio
axon
densiti
site
cvsm
control
hors
term
ccpr
plot
tmmep
latenc
craniali
tibiali
muscl
examin
correl
individu
funiculu
axon
densiti
sever
affect
transvers
section
plot
tmmep
latenc
craniali
tibilai
muscl
investig
effect
locat
within
spinal
cord
tmmep
latenc
show
signific
differ
group
craniali
tibiali
muscl
exclus
craniali
tibiali
tmmep
latenc
linearli
correl
ccpr
loss
axon
sever
ventromedi
funiculi
cvsm
hors
data
confirm
hors
affect
cvsm
prolong
tmmep
latenc
tmmep
latenc
correl
sever
axon
loss
find
indic
tmmep
might
use
identifi
quantifi
sever
spinal
cord
damag
clinic
cvsm
sever
ventral
funicular
chang
uniqu
find
might
suggest
area
vulner
injuri
hors
cvsm
previous
recogn
steev
elisa
londa
mari
jennif
sonsiray
noah
marilyn
jose
georgia
athen
georgia
usa
edinburgh
edinburgh
uk
univers
colleg
station
texa
usa
washington
seattl
washington
usa
incid
macrolid
rifampin
resist
r
equi
isol
foal
increas
consider
recent
year
object
studi
identifi
molecular
mechan
emerg
macrolid
resist
r
equi
determin
transfer
n
macrolid
suscept
n
clinic
isol
r
equi
foal
usa
studi
whole
genom
sequenc
sampl
r
equi
perform
pcr
use
screen
presenc
resist
determin
isol
mate
experi
perform
document
transfer
determin
genom
resist
isol
virtual
ident
wherea
mark
chromosom
variabl
among
suscept
isol
suggest
expans
resist
clone
novel
erm
gene
erm
identifi
resist
isol
perfect
associ
macrolid
resist
presenc
erm
detect
pcr
isol
r
equi
express
erm
strain
r
equi
induc
high
level
resist
macrolid
lincosamid
streptogramin
b
class
antimicrobi
agent
transfer
erm
resist
suscept
strain
r
equi
confirm
occur
transfer
frequenc
first
molecular
character
macrolid
lincosamid
streptogramin
b
resist
r
equi
resist
caus
novel
erm
gene
erm
transferr
like
conjug
ashley
darko
shelley
studi
new
bolton
center
univers
pennsylvania
kennett
squar
pennsylvania
usa
veterinari
medicin
pathobiolog
univers
pennsylvania
philadelphia
pennsylvania
usa
hypothes
sampl
obtain
guttur
pouch
would
sensit
sampl
obtain
nasopharynx
identifi
carrier
streptococcu
equi
equi
isotherm
lamp
pcr
assay
target
eqb
gene
would
sensit
realtim
pcr
assay
target
seei
gene
three
sampl
collect
hors
nasopharyng
flock
nylon
swab
npf
nasopharyng
wash
npw
guttur
pouch
lavag
gpl
eqb
lamp
assay
perform
npf
npw
gpl
sampl
gpl
sampl
split
aliquot
equi
cultur
eqb
lamp
seei
realtim
pcr
logist
regress
area
curv
roc
perform
use
stata
consid
signific
total
sampl
obtain
hors
npf
npw
gpl
npf
npw
gpl
sampl
posit
eqb
lamp
gpl
sampl
posit
seei
pcr
equi
isol
gpl
sampl
gpl
best
sampl
detect
carrier
compar
npf
p
npw
p
eqb
lamp
result
compar
endoscop
abnorm
guttur
pouch
sensit
specif
lamp
roc
seei
pcr
roc
sensit
specif
eqb
lamp
compar
seei
pcr
roc
studi
demonstr
gpl
use
detect
equi
carrier
eqb
lamp
assay
compar
seei
pcr
benjamin
uberti
natalia
moral
constanza
borlon
claudio
sarmiento
gabriel
universidad
austral
de
chile
valdivia
de
lo
chile
equin
recurr
airway
obstruct
rao
sever
limit
athlet
function
qualiti
life
adult
hors
inhal
varieti
environment
allergen
induc
chronic
respiratori
inflamm
lead
lower
airway
increas
product
mucu
airway
remodel
swell
narrow
airway
lead
decreas
lung
function
limit
ga
exchang
evid
mani
cell
structur
lung
play
import
role
pathophysiolog
diseas
contribut
bronchial
epitheli
cell
vascular
endothelium
lymphoid
myeloid
cell
well
document
interact
allergen
resid
innat
immun
cell
induc
arriv
inflammatori
cell
via
cytokin
chemokin
inflammatori
reaction
fulfil
task
mechan
take
stage
chemokin
signal
lead
abrog
inflammatori
cell
influx
mainli
neutrophil
neutrophil
initi
apoptot
program
releas
molecul
attract
macrophag
turn
perform
neutrophil
clearanc
phagocytosi
apoptot
neutrophil
eventu
reprogram
macrophag
toward
phenotyp
success
complet
mechan
lead
restor
tissu
homeostasi
preliminari
result
demonstr
tamoxifen
select
estrogen
receptor
modul
use
treatment
stage
human
breast
cancer
mark
effect
equin
neutrophil
function
apoptosi
vitro
result
show
tamoxifen
significantli
inhibit
neutrophil
chemotaxi
hors
human
respons
onward
p
anova
addit
tamoxifen
significantli
inhibit
product
reactiv
oxygen
speci
onward
earli
neutrophil
apoptosi
induc
approxim
cell
minut
incub
tamoxifen
sarmiento
perez
moral
et
al
induct
apoptosi
coincid
vivo
result
neutrophil
obtain
anim
show
mark
increas
earli
apoptosi
iv
po
pharmacokinet
analysi
tamoxifen
hors
current
way
trial
perform
recent
stall
hors
acut
exacerb
rao
treat
tamoxifen
mg
po
q
hour
day
dose
extrapol
human
murin
pharmacokinet
data
hors
receiv
treatment
underw
manag
chang
mark
decreas
bronchoalveolar
lavag
neutrophil
count
treatment
day
day
clinic
paramet
spirometri
respiratori
rate
pattern
improv
day
treatment
onward
tracheal
mucu
content
chang
significantli
cours
treatment
result
suggest
tamoxifen
effect
neutrophil
surviv
pulmonari
environ
warrant
investig
recruit
addit
subject
acut
exacerb
rao
ongo
allison
lauren
melodi
de
christoph
veroniqu
state
univers
stillwat
oklahoma
usa
queensland
brisban
queensland
australia
equin
metabol
syndrom
increasingli
recogn
diseas
character
obes
insulin
resist
although
hyperinsulinemia
predispos
hors
develop
lamin
exact
relationship
condit
remain
undetermin
hypothes
gene
express
protein
involv
downstream
insulin
signal
glucos
transport
pathway
alter
prolong
lamin
standardbr
hors
treat
prolong
euglycaem
hyperinsulinaem
clamp
hour
balanc
electrolyt
solut
gene
express
key
protein
involv
insulin
signal
pathway
evalu
archiv
striat
muscl
lamellar
sampl
use
revers
transcript
pcr
primer
select
insulin
receptor
glycogen
synthas
kinas
beta
gene
express
basal
glucos
transport
evalu
use
group
becam
markedli
hyperinsulinaem
maintain
normoglycemia
develop
clinic
lamin
signific
differ
gene
express
skelet
muscl
lamellar
tissu
group
contrast
signific
upregul
express
cardiac
tissu
group
compar
control
p
data
suggest
prolong
euglycaemia
hyperinsulinaem
clamp
induc
increas
insulin
sensit
heart
well
transcript
activ
glucos
transport
addit
lack
downregul
insulin
signal
pathway
skelet
muscl
digit
lamella
support
insulin
resist
requir
onset
lamin
carlo
e
christoph
c
clair
e
matia
mark
p
dean
w
andrew
w
van
equin
lamin
research
unit
school
veterinari
scienc
univers
queensland
gatton
queensland
australia
australia
queensland
node
australian
institut
bioengin
nanotechnolog
univers
queensland
brisban
queensland
australia
bolton
center
depart
clinic
studi
school
veterinari
medicin
univers
pennsylvania
kennett
squar
pennsylvania
usa
disrupt
cellular
energi
pathway
may
play
role
differ
form
lamin
aim
work
character
normal
lamellar
bioenerget
profil
establish
chang
metabolit
pattern
microvascular
perfus
occur
result
modif
limb
load
cycl
activ
develop
experiment
induc
lamin
first
microdialysi
techniqu
serial
measur
lamellar
tissu
energi
metabolit
glucos
lactat
pyruv
urea
glycerol
hour
period
develop
lamellar
energi
profil
clinic
normal
hors
character
subsequ
hors
instrument
lamellar
skin
microdialysi
probe
subject
sequenti
intervent
design
modifi
tissu
perfus
intervent
limb
load
cycl
activ
weight
bear
intervent
urea
mmoll
ad
perfus
fluid
investig
urea
clearanc
uc
method
use
assess
local
blood
flow
could
identifi
lamellar
perfus
chang
energi
metabolit
concentr
uc
standard
indic
energi
metabol
lactat
glucos
l
g
lactat
pyruv
l
p
ratio
determin
intervent
chang
lamellar
bioenerget
composit
perfus
develop
experiment
induc
lamin
investig
hors
treatment
n
control
n
hors
receiv
oligofructos
water
via
nasogastr
tube
lamellar
metabolit
composit
l
g
l
p
uc
determin
bihourli
compar
lastli
use
lamellar
skin
dialys
tissu
section
healthi
hors
n
lamellar
dialys
oft
n
con
n
hors
target
metabolom
analysi
ie
central
carbon
metabolit
ccm
perform
use
liquid
chromatographi
coupl
tandem
mass
spectrometri
differ
lamella
skin
healthi
hors
differ
oft
con
hors
investig
intervent
studi
uc
alon
combin
fluctuat
energi
metabolit
pattern
detect
profound
mild
chang
lamellar
perfus
respect
signific
chang
lamellar
energi
metabolit
composit
uc
observ
limb
load
cycl
activ
modifi
increas
glucos
uc
compat
increas
lamellar
perfus
observ
limb
activ
increas
studi
glucos
decreas
significantli
oft
lamellar
dialys
consist
lower
oft
con
hors
lactat
higher
oft
skin
compar
pyruv
decreas
significantli
significantli
less
l
g
l
p
increas
significantli
urea
decreas
significantli
increas
uc
remain
stabl
hyperaemia
rather
ischaemia
togeth
bioenerget
disturb
occur
development
phase
lamin
though
perfus
increas
lamellar
glucos
markedli
reduc
could
compromis
lamellar
basal
epitheli
cell
metabol
despit
lack
definit
evid
lamellar
bioenerget
failur
metabolom
analysi
lamellar
skin
dialys
show
differ
metabolit
composit
two
tissu
healthi
hors
metabolom
dialys
tissu
sampl
also
found
similar
differ
ccm
oft
con
hors
observ
metabolom
analysi
lamellar
ccm
capabl
differenti
oft
con
hors
lamellar
malat
pyruv
aconit
glycol
identifi
sourc
differenti
oft
con
group
studi
demonstr
lamellar
microdialysi
uc
use
assess
lamellar
bioenerget
perfus
chang
microdialysi
uc
suggest
increas
lamellar
perfus
develop
lamin
find
also
suggest
lamellar
perfus
energi
balanc
may
relat
limb
load
cycl
particularli
affect
ambul
support
hypothesi
reduc
limb
load
cycl
increas
weight
bear
may
associ
reduc
lamellar
perfus
melodi
de
laat
jessica
van
haeften
martin
sillenc
queensland
univers
technolog
brisban
queensland
australia
equin
insulin
secret
vari
individu
affect
diet
metabol
statu
dysregul
result
hyperinsulinaemia
signific
lamin
risk
gastrointestin
hormon
may
exacerb
insulin
respons
feed
studi
investig
whether
incretin
hormon
insulinotrop
peptid
gip
augment
insulin
secret
follow
oral
glucos
compar
intraven
glucos
infus
poni
n
receiv
mgkg
low
glycaem
ration
bw
assay
valid
insulin
glucos
incretin
analysi
blood
sampl
collect
everi
minut
hour
feed
seven
day
later
experi
replic
howev
administ
intraven
variabl
rate
match
individu
meal
consumpt
minut
poni
stratifi
insulin
sensit
statu
use
basal
valuesproxi
although
intraven
glucos
elicit
larger
area
curv
insulin
aucinsulin
insulin
respons
oral
glucos
larger
p
bimod
compar
poni
correl
well
aucglucos
importantli
insulin
resist
affect
insulin
respons
intraven
glucos
wherea
oral
glucos
aucinsulin
aucglucos
higher
p
poni
secret
gip
higher
p
follow
oral
glucos
compar
intraven
posit
correl
p
insulin
oral
glucos
stimul
larger
p
poni
thu
larger
insulin
respons
oral
glucos
poni
like
due
part
incretin
action
particular
may
key
factor
equin
insulin
dysregul
nicola
pusterla
andrea
packham
sarah
macki
philip
kass
laszlo
hunyadi
patricia
conrad
svm
uc
davi
davi
california
usa
therapeut
treatment
strategi
prevent
sarcocysti
neurona
infect
hors
empir
pellet
top
dress
diclazuril
drug
recent
introduc
equin
market
label
treatment
equin
protozo
myeloenceph
epm
potenti
use
prevent
epm
due
conveni
formul
diclazuril
given
mgkg
bodi
weight
shown
reach
plasma
cerebrospin
fluid
concentr
excess
minim
concentr
known
inhibitori
neurona
merozoit
product
cell
cultur
purpos
studi
evalu
tempor
serolog
respons
neurona
foal
receiv
daili
diclazuril
untreat
herdmat
foal
farm
high
exposur
rate
neurona
randomli
assign
either
untreat
control
group
diclazuril
treat
group
treatment
consist
administr
mgkg
bodi
weight
diclazuril
pellet
top
dress
start
week
age
foal
month
age
whole
blood
collect
everi
dam
foal
hour
monthli
thereaft
everi
studi
foal
durat
studi
blood
test
igg
neurona
use
indirect
fluoresc
antibodi
test
follow
ingest
colostr
antibodi
neurona
steadi
continu
declin
seropreval
antibodi
titer
neurona
foal
group
reach
wean
age
thereaft
untreat
foal
show
increas
monthli
seropreval
rang
diclazuril
treat
foal
show
signific
lower
monthli
seropreval
rang
end
studi
untreat
treat
foal
respect
test
seroposit
neurona
conclus
daili
supplement
diclazuril
pellet
top
dress
mgkg
bodi
weight
demonstr
signific
reduct
seroconvers
neurona
diclazuril
treat
control
foal
month
age
author
knowledg
first
report
determin
dose
durat
treatment
prevent
seroconvers
foal
origin
farm
high
infect
rate
neurona
econom
standpoint
supplement
diclazuril
earli
exposur
period
may
benefit
hors
industri
reduc
cost
associ
epm
melodi
de
laat
jessica
van
haeften
martin
sillenc
queensland
univers
technolog
brisban
queensland
australia
manag
equin
hyperinsulinaemia
crucial
prevent
lamin
secret
pancrea
proport
insulin
use
studi
insulin
dysregul
assay
valid
thoroughli
hors
studi
aim
identifi
suitabl
immunoassay
equin
compar
secret
follow
oral
iv
dextros
administr
poni
seven
assay
assess
precis
accuraci
specif
one
assay
deem
accept
use
measur
respons
nine
poni
oral
iv
dextros
mgkg
poni
design
ir
base
fast
ratio
oral
glucos
test
concentr
increas
rapidli
fast
level
follow
oral
p
iv
p
dextros
similar
auc
test
insulin
concentr
correl
p
auc
compar
similar
ir
poni
iv
dextros
howev
oral
dextros
higher
p
ir
compar
poni
insulin
clearanc
fraction
differ
greater
oral
test
poni
minut
dextros
administr
test
wherea
insulin
respons
iv
dextros
indic
pancreat
capac
similar
group
ir
poni
maintain
magnitud
respons
oral
dextros
increas
insulin
secret
major
compon
hyperinsulinaemia
although
reduc
clearanc
also
appear
contribut
increas
capac
insulin
respons
oral
carbohydr
ir
poni
derek
knottenbelt
nicola
kerbyson
timothi
parkin
univers
glasgow
glasgow
uk
preval
colon
ulcer
previous
state
larg
studi
hors
although
lesion
defin
grossli
histopatholog
detail
gross
histolog
examin
gastrointestin
tract
hors
euthan
reason
unrel
gastrointestin
tract
reveal
grossli
obviou
colon
mucos
patholog
case
consid
like
clinic
signific
includ
sand
enteropathi
activ
cyathostominosi
right
dorsal
coliti
focal
diffus
colon
ulcer
focal
congest
caecum
ventral
colon
right
dorsal
colon
hors
small
colon
obviou
visual
clinic
signific
equivoc
studi
demonstr
rang
larg
intestin
mucos
patholog
may
present
even
absenc
overt
clinic
sign
subclin
larg
colon
caecal
diseas
consid
case
sign
abdomin
diseas
although
specif
diagnosi
case
would
requir
signific
invas
investig
rectal
biopsi
consid
poorli
correl
condit
identifi
concur
recent
research
minim
invas
diagnost
test
fecal
occult
blood
fecal
ph
detail
microbiota
panel
need
establish
allow
effect
accur
diagnosi
need
correl
close
clearer
definit
rang
clinic
diseas
identifi
patholog
studi
refer
pellegrini
fl
result
necroscop
studi
equin
colon
ulcer
j
equin
vet
sci
mar
van
mm
grinwi
gcm
variat
eosinophil
infiltr
within
rectal
mucosa
clinic
healthi
hors
proceed
equin
colic
symposium
dublin
ireland
jonathan
foreman
catherin
foreman
benjamin
bergstom
univers
illinoi
urbana
illinoi
usa
treatment
acut
equin
foot
pain
lamin
convent
treatment
includ
cox
inhibitor
phenylbutazon
pbz
flunixin
meglumin
fm
inhibitor
convent
nsaid
known
caus
side
effect
gastrointestin
ulcer
renal
diseas
veterinarian
treat
lamin
often
search
efficaci
altern
convent
nsaid
hypothesi
seri
experi
therapi
would
shown
similar
convent
nsaid
treatment
acut
equin
foot
pain
revers
model
lame
hors
hors
shod
adjust
heart
bar
shoe
one
foot
hors
monitor
blind
investig
variabl
includ
hr
lame
score
result
compar
rm
anova
tukey
test
signific
set
p
firocoxib
mgkg
iv
differ
salin
less
effect
pbz
mgkg
iv
p
firocoxib
load
dose
mgkg
iv
similar
efficaci
pbz
mgkg
iv
acetaminophen
mgkg
po
oral
fm
mgkg
po
administ
separ
compar
one
anoth
better
salin
p
acetaminophen
mgkg
po
bid
combin
firocoxib
mgkg
sid
similar
pbz
mgkg
iv
bid
regim
better
salin
p
studi
intraven
firocoxib
load
dose
mgkg
iv
sid
oral
acetaminophen
show
promis
allevi
acut
equin
foot
pain
julia
montgomeri
katharina
lohmann
bonni
chaban
lisa
johnson
scott
do
santo
jordan
steedman
janet
e
hill
western
colleg
veterinari
medicin
univers
saskatchewan
saskatoon
saskatchewan
canada
microbi
commun
colon
airway
may
play
role
develop
chronic
inflammatori
airway
diseas
investig
whether
may
true
equin
heav
character
tracheal
microbiom
three
healthi
hors
five
hors
histor
clinic
andor
bronchoalveolar
lavag
cytolog
find
consist
heav
two
occas
approxim
week
apart
tracheal
aspir
ta
sampl
collect
transendoscop
use
sampl
cathet
total
genom
dna
extract
one
aliquot
dna
integr
verifi
pcr
amplif
hors
mitochondri
gene
total
bacteri
load
estim
quantit
pcr
target
rrna
gene
pcr
amplicon
librari
base
univers
kda
chaperonin
gene
prepar
use
establish
protocol
sequenc
use
gs
junior
pyrosequenc
platform
sequenc
assembl
oper
taxonom
unit
otu
compar
cpndb
refer
databas
wwwcpndbca
identifi
closest
refer
sequenc
nearest
neighbor
otu
phylum
assign
otu
sequenc
base
taxonom
lineag
nearest
cpndb
refer
sequenc
alpha
beta
divers
calcul
use
qiim
hierarch
cluster
microbiom
profil
perform
r
second
aliquot
sampl
underw
routin
microbiolog
analysi
use
aerob
cultur
blood
mcconkey
agar
plate
follow
biochem
test
identif
coloni
per
microbiolog
cultur
plate
amplifi
use
univers
primer
pcr
sequenc
compar
microbiom
librari
correspond
hors
total
ta
sampl
avail
analysi
five
hors
heav
two
activ
diseas
time
sampl
three
consid
remiss
total
bacteri
load
number
rrna
copi
per
ml
ta
appear
higher
hors
heav
although
consider
variat
exist
within
group
sampl
total
sequenc
read
analyz
median
per
sampl
rang
consist
rrna
copi
number
microbiom
hors
heav
appear
higher
speci
rich
healthi
hors
microbiom
profil
hors
clinic
categori
domin
firmicut
actinobacteria
proteobacteria
otu
sequenc
correspond
nearest
neighbor
refer
sequenc
otu
similar
pseudomona
fluorescen
rothia
spp
pantoea
agglomeran
streptococcu
spp
preval
among
sampl
frequent
abund
individu
microbiom
phylum
level
profil
hierarch
cluster
otu
level
profil
base
dissimilar
show
microbiom
profil
individu
hors
larg
similar
two
sampl
microbiom
cluster
clinic
categori
sequenc
data
obtain
bacteri
coloni
repres
uniqu
sequenc
sequenc
ident
otu
relev
microbiom
librari
speci
identifi
cultur
microbiom
sequenc
includ
firmicut
repres
sequenc
data
gener
hors
consist
comprehens
view
microbiom
provid
approach
conclus
pilot
studi
suggest
hors
heav
may
higher
bacteri
load
greater
speci
rich
microbiom
profil
distinguish
healthi
hors
phylum
otu
level
hors
tracheal
microbiom
appear
stabl
time
frame
studi
microbiom
analysi
genet
level
enhanc
assess
microbi
commun
compar
convent
cultur
method
work
ongo
confirm
initi
find
larger
group
hors
benjamin
john
binu
paul
univers
auburn
alabama
usa
anim
diseas
center
ame
iowa
usa
veterinari
medic
diagnost
laboratori
amarillo
texa
usa
bovin
viru
widespread
respiratori
pathogen
cattl
capabl
caus
diseas
uniqu
pathogen
commonli
predispos
cattl
secondari
bacteri
infect
develop
pneumonia
genotyp
unit
state
us
recent
report
littl
known
pathogen
shed
compar
therefor
purpos
pilot
studi
compar
pathogen
shed
clinic
us
isol
three
genotyp
b
c
sixteen
wean
jersey
bull
calv
seroneg
randomli
assign
one
four
group
calv
challeng
intranas
approxim
one
genotyp
serv
neg
control
calv
maintain
isol
room
daili
nasal
swab
collect
observ
sign
diseas
blind
investig
perform
throughout
studi
mild
clinic
sign
observ
similarli
challeng
group
includ
serou
nasal
discharg
cough
onset
nasal
shed
differ
group
challeng
calv
shed
begin
day
challeng
calv
day
challeng
calv
day
shed
last
day
shed
virus
extend
day
studi
demonstr
differ
shed
dynam
genotyp
katharin
robert
sarah
caitlin
joseph
ohio
state
univers
columbu
ohio
usa
state
univers
stillwat
oklahoma
usa
obstruct
urolithiasi
male
small
rumin
common
metabol
diseas
often
requir
surgic
intervent
temporari
perman
urinari
divers
indic
urethr
process
amput
andor
retrograd
urethr
hydropuls
unsuccess
restor
urethr
patenc
surgic
cystostomi
tube
placement
often
consid
treatment
choic
allow
urinari
divers
ultim
reestablish
urethr
patenc
howev
cost
associ
gener
anesthesia
surgeri
care
substanti
advantag
percutan
tube
cystostomi
rather
surgic
tube
cystostomi
placement
includ
shorten
procedur
time
provis
rapid
urinari
divers
system
compromis
patient
complic
gener
anesthesia
avoid
procedur
perform
util
local
anesthesia
without
sedat
describ
use
commerci
avail
suprapub
percutan
tube
cystostomi
conjunct
urinari
acidif
primari
treatment
modal
case
obstruct
urolithiasi
goat
suspect
confirm
struvit
urolithiasi
five
goat
four
pygmi
one
diagnos
obstruct
urolithiasi
retrograd
urethr
catheter
unsuccess
reliev
obstruct
four
goat
goat
consid
emerg
poor
anesthet
candid
rutner
suprapub
percutan
insert
urinari
bladder
util
ultrasound
guidanc
five
goat
provid
urinari
divers
patenc
urethra
reestablish
goat
mean
median
cost
associ
percutan
cystostomi
respect
compar
mean
median
associ
surgic
tube
cystostomi
year
complic
note
includ
obstruct
cathet
n
transient
uroabdomen
urethr
ruptur
base
outcom
suggest
percutan
tube
cystostomi
use
commerci
avail
rutner
suprapub
fr
ml
balloon
conjunct
urinari
acidif
may
use
altern
surgic
intervent
treatment
obstruct
urolithiasi
particularli
case
urolith
amen
dissolut
addit
research
indic
fulli
elucid
complic
prognosi
suprapub
balloon
cathet
set
medic
french
ml
balloon
john
daniela
mark
g
school
veterinari
medicin
tuft
univers
grafton
massachusett
usa
carolina
state
univers
raleigh
north
california
usa
studi
purpos
determin
pharmacokinet
pk
clinic
effect
extend
releas
eprinomectin
merial
follow
subcutan
sc
inject
healthi
n
n
adult
alpaca
liquid
chromatographi
perform
plasma
sampl
obtain
regular
interv
follow
singl
mgkg
inject
sc
healthi
alpaca
follow
dose
treatment
month
apart
mang
affect
anim
clinic
monitor
includ
biweekli
hematolog
physic
examin
monthli
weight
fecal
egg
count
centrifug
skin
scrape
biopsi
perform
two
compar
site
alpaca
mang
four
alpaca
serv
healthi
control
pharmacokinet
analysi
util
model
result
compar
use
anova
pair
sampl
eprinomectin
plasma
concentr
show
biphas
peak
anim
eprinomectin
plasma
concentr
remain
ngml
day
hematocrit
versu
p
albumin
versu
gdl
p
reduc
significantli
month
anim
fec
differ
group
reaction
occur
anim
skin
biopsi
show
reduc
hyperkeratosi
increas
fibrosi
alpaca
remain
posit
skin
scrape
mang
conclus
alpaca
requir
higher
eprinomectin
dose
mgkg
sc
cattl
reach
compar
plasma
concentr
meredyth
jone
allen
roussel
w
shawn
ramsey
texa
univers
colleg
station
texa
usa
studi
urolithiasi
small
rumin
hamper
lack
conveni
reliabl
model
would
allow
quantit
assess
calculogen
potenti
ration
object
studi
develop
nonsurg
experiment
model
urolithiasi
goat
ten
old
doel
fed
calculogen
diet
design
promot
struvit
urolithiasi
zinc
washer
mm
diamet
use
washer
tie
wrap
chromic
catgut
polyest
fiber
sutur
goat
anesthet
implant
place
lumen
urinari
bladder
retrograd
urethra
differ
combin
washer
size
sutur
materi
pattern
use
separ
experi
end
experi
day
placement
implant
retriev
via
urethra
two
implant
requir
remov
via
cystotomi
due
larg
amount
crystallin
precipit
across
experi
implant
spontan
pass
implant
remain
bladder
end
experi
grossli
visibl
calculu
accumul
disc
sutur
materi
accumul
mgday
compar
mgday
without
sutur
materi
urolith
analysi
reveal
predomin
materi
accumul
either
struvit
amorph
magnesium
calcium
phosphat
studi
demonstr
urolith
creat
consist
nonsurg
model
goat
model
use
studi
ration
evalu
intervent
may
reduc
prevent
format
urinari
calculi
small
rumin
manuel
f
paul
h
thoma
kay
benjamin
roberto
univers
auburn
alabama
usa
georgia
athen
georgia
usa
object
studi
evalu
efficaci
differ
multival
mlv
vaccin
prevent
clinic
diseas
viremia
viru
shed
earli
wean
beef
calv
challeng
bvdv
bvdv
first
studi
beef
calv
earli
wean
median
age
day
assign
treatment
group
control
vaccin
b
vaccin
c
vaccin
day
vaccin
calv
challeng
intranas
virul
bvdv
second
studi
beef
calv
earli
wean
median
age
day
assign
treatment
group
control
vaccin
b
vaccin
c
vaccin
vaccin
e
day
vaccin
calv
simultan
expos
cattl
pi
bvdv
calv
acut
infect
sampl
collect
calv
viru
isol
viru
neutral
analysi
vaccin
viru
challeng
calv
vaccin
vaccin
b
c
first
studi
calv
vaccin
vaccin
b
c
e
second
studi
greater
respons
lower
proport
viremia
bvdv
shed
compar
control
vaccin
earli
wean
beef
calv
result
increas
bvdv
antibodi
respons
reduc
viremia
bvdv
shed
differ
vaccin
efficaci
prevent
bvdv
viremia
shed
observ
fecteau
helen
aceto
terri
fyock
raymond
sweeney
school
veterinari
medicin
univers
pennsylvania
kennett
squar
pennsylvania
usa
john
diseas
jd
affect
approxim
us
dairi
caus
great
econom
loss
dairi
produc
qualifi
label
organ
certain
restrict
manag
practic
may
predispos
transmiss
jd
farm
object
compar
jd
preval
pennsylvania
organ
convent
dairi
farm
identifi
risk
factor
associ
differ
jd
preval
jd
milk
elisa
perform
individu
milk
sampl
lactat
cow
studi
herd
inform
regard
manag
practic
collect
farm
visit
overal
herd
preval
preval
compar
group
logist
regress
use
identifi
risk
factor
associ
differ
jd
preval
group
total
cow
herd
organ
convent
includ
studi
median
herd
size
rang
cow
convent
farm
rang
cow
organ
farm
farm
includ
studi
posit
posit
convent
farm
posit
organ
farm
convent
farm
cow
posit
compar
cow
organ
herd
adjust
herd
size
signific
differ
herd
preval
p
preval
p
convent
organ
farm
risk
factor
current
analyz
preliminari
result
indic
differ
jd
preval
pennsylvania
organ
convent
dairi
farm
kelli
pipkin
jill
hagey
mair
rayburn
munash
chigerw
uc
davi
davi
california
usa
object
studi
determin
rate
catabol
colostr
deriv
igg
administ
oroesophag
tube
compar
iv
administ
plasma
igg
random
clinic
trial
perform
thirti
newborn
jersey
calv
enrol
fifteen
fed
colostrum
cl
group
given
bovin
plasma
iv
pl
group
calv
cl
group
fed
l
colostrum
oroesophag
tube
calv
pl
group
given
plasma
iv
dosag
mlkg
serum
fecal
sampl
collect
hour
hour
hour
hour
day
day
serum
fecal
igg
concentr
determin
radial
immunodiffus
calv
cl
group
maintain
serum
igg
concentr
consist
adequ
transfer
immun
mgdl
throughout
studi
period
calv
pl
group
achiev
median
igg
concentr
mgdl
hour
concentr
mgdl
hour
calv
pl
group
time
like
experi
mortal
compar
cl
group
hazard
ratio
fecal
igg
concentr
differ
group
first
hour
p
catabol
plasma
deriv
igg
occur
rapidli
first
hour
transfus
fecal
excret
explain
fate
plasma
deriv
igg
christian
hanspet
maud
claudin
endr
maja
sandro
faculti
univers
zurich
zurich
switzerland
genom
center
zurich
zurich
switzerland
transit
time
around
parturit
earli
lactat
involv
critic
physiolog
chang
dairi
cow
excess
demand
nutrient
due
increas
perform
requir
milk
product
result
neg
energi
balanc
one
major
adjust
consist
rapid
mobil
energi
sourc
tissu
depot
form
fatti
acid
cow
poorli
adapt
neb
high
risk
develop
diseas
mani
transit
period
diseas
includ
fatti
liver
occur
subclin
form
affect
milk
product
reproduct
perform
dairi
cow
fatti
liver
interrel
product
diseas
noninvas
accur
test
would
help
diagnos
fatti
liver
cattl
purpos
screen
approach
provid
hypothesi
develop
novel
diagnost
test
base
lipidom
profil
less
invas
accur
compar
plasma
lipidom
diseas
dairi
cow
use
liquid
chromatographi
coupl
quadrupol
mass
spectrometri
studi
cow
reveal
mass
could
distinguish
healthi
cow
cow
differ
stage
diseas
studi
clinic
healthi
cow
transit
period
mass
could
analyz
msm
potenti
biomark
determin
chang
within
lipidom
rel
calv
main
lipid
group
detect
triacylglycerid
phosphatidylcholin
lysophosphatidylcholin
teresa
nandini
de
de
quebec
canada
medic
scienc
univers
madison
wisconsin
usa
medicin
depart
epidemiolog
biostatist
occup
health
mcgill
univers
quebec
canada
gold
standard
method
diagnosi
bovin
respiratori
diseas
brd
complex
holstein
dairi
calv
systemat
thorac
ultrasonographi
tu
use
proxi
brd
perform
field
veterinarian
directli
use
produc
tu
examin
focus
lung
consolid
common
find
bronchopneumonia
wisconsin
calf
respiratori
score
chart
crsc
simpler
altern
systemat
assess
rectal
temperatur
cough
ear
posit
nasal
ocular
discharg
attribut
score
item
well
decis
base
total
score
obtain
ie
noth
monitor
treat
howev
accuraci
crsc
still
unknown
object
estim
accuraci
crsc
two
differ
popul
adjust
lack
defin
brd
statu
two
cross
section
studi
popul
high
brd
preval
n
holstein
calv
averag
brd
preval
n
holstein
calv
north
america
studi
calv
simultan
assess
use
crsc
cutoff
tu
cutoff
cm
lung
consolid
use
tu
gold
standard
crsc
se
sp
respect
bayesian
latent
class
model
condit
depend
use
inform
prior
brd
preval
set
tu
accuraci
sensit
setu
specif
sptu
prior
crsc
accuraci
secrsc
spcrsc
secrsc
credibl
interv
ci
spcrsc
setu
sptu
sensit
analysi
reveal
result
robust
prior
specif
despit
imperfect
accuraci
tool
help
brd
manag
improv
accuraci
brd
detect
key
step
decreas
neg
impact
well
overus
antimicrobi
fals
posit
case
maria
prado
john
wilkerson
peter
krawczel
chri
boyer
arnold
saxton
univers
tennesse
knoxvil
tennesse
usa
dairi
calf
pneumonia
dcp
continu
highli
preval
condit
affect
calv
andor
period
howev
impact
extend
beyond
actual
diseas
episod
neg
effect
subsequ
product
surviv
replac
stock
abil
identifi
calv
initi
stage
respiratori
diseas
develop
monitor
activ
feed
behavior
would
allow
earlier
diseas
intervent
thu
potenti
decreas
effect
dcp
later
calf
life
therefor
object
studi
determin
impact
differ
milk
feed
level
standard
high
hous
individu
group
respiratori
diseas
develop
subsequ
product
young
dairi
calv
femal
holstein
calv
n
commerci
dairi
farm
use
studi
calv
randomli
assign
one
three
treatment
group
individu
hutch
standard
milk
lday
individu
hutch
high
milk
lday
pair
hutch
calv
standard
milk
random
block
design
social
interactionact
level
well
feed
behavior
measur
fit
calv
collar
contain
sensor
period
calv
screen
daili
clinic
sign
diseas
dcp
confirm
pcr
serolog
bodi
weight
collect
wean
calv
data
collect
analyz
identifi
behavior
chang
social
interact
andor
feed
associ
develop
respiratori
diseas
serum
sampl
collect
determin
passiv
transfer
hour
birth
farm
record
use
evalu
effect
manag
phase
health
product
calv
retrospect
analysi
autom
sensor
system
success
record
activ
level
calv
differ
treatment
group
total
activ
level
correl
milk
consumpt
show
signific
increas
time
preced
feed
addit
establish
uniqu
time
seri
signatur
acceler
data
activ
level
correspond
normal
specif
behavior
sleep
stand
walk
andor
bottl
feed
use
data
identifi
deviat
norm
overal
respiratori
diseas
level
farm
low
calv
develop
diarrhea
move
hutch
calv
high
milk
group
gain
averag
lbsday
versu
lbsday
control
group
averag
daili
gain
compar
calv
high
milk
group
pair
group
lb
overal
calv
fed
high
milk
level
gain
weight
incid
respiratori
diseas
low
enrol
calv
milk
yield
health
reproduct
data
present
